Engaging the Community
Annual 2010 Report
1 CovBc.indd 2 11/9/10 5:39 PM President & Chairman’s Message
Throughout our 60+ year history, The Leukemia & Lymphoma Society (LLS) has been committed to being innovative in all ways to find cures for blood cancers and improve the lives of patients and their families.
Using social media is one such innovation. Its vast reach and immediacy provide a better way for people to connect and has changed the way we communicate in our daily lives. We saw its potential as a way to efficiently connect more directly with our patients, friends and supporters early on when we created the LLS blog and transferred our discussion boards to our own social network over two years ago.
In the past year, we decided to more fully capitalize on this growing and effective communications venue. We realized that expanding our social media network would help us more fully engage all members of the LLS community while showcasing www.lls.org, our National website. People interact online – “posting,” “tweeting,” “following,” “liking” and “chatting” every day, and it made sense for us to do likewise. So we added new blogs, expanded our discussion boards, enhanced our webcast series and increased our presence on popular social networking sites such as Facebook, Twitter and YouTube.
We’re proud to say that our efforts have paid off. As this year’s Annual Report shows, our expanded social networking presence has made a difference in the key areas of Patient Services, Fundraising, Advocacy and Research. Visit our online community and you’ll see cancer patients and survivors interacting on discussion boards, “commenting” on our Facebook Fan Pages, “retweeting” our Twitter posts, and blogging on a myriad of cancer-related topics.
Social media lets us reach the LLS community faster and more efficiently than ever before. We are where you are. Together, we will continue to make progress in our fight against blood cancers.
John E. Walter Steven L. Hooker President and CEO Chair
p1-13.indd 1 11/9/10 4:47 PM Engaging the LLS Communities
First Connection is an amazing resource. I remember last year feeling so lost Melynn LLS Fan Page and I received a call from someone who was about 52 when she got ALL. She’s been cancer-free for over 12 years! I have her name and number tucked in my notebook and am so thankful for that phone call.
Commenting on the LLS blog post, “First Connection, Lasting Friendships”
2
p1-13.indd 2 11/9/10 4:47 PM Social media combines the vast reach of a massive audience with the intimacy of a personal conversation. Used extensively by our Home Office and chapters throughout the US and Canada to support the LLS community, it also provides efficient channels for our patients, fundraisers, researchers and supporters to correspond quickly and easily with each other.
People with similar interests and issues can “talk” to each other whenever and wherever they like – whether it’s galvanizing support nationwide to affect legislation, promoting a local LLS fundraiser, or discussing how to cope with treatment side effects – social media moves our mission forward. Fiscal year 2010 saw a 56% increase in the size of our social networking community, which now exceeds 1.7 million contacts. When you consider that each person, on average, is linked into several other online networks, you understand the potential of what can be accomplished by keeping our online community engaged.
In addition to expanding our social media presence on the leading networks, we’ve enhanced our own social network (located at community.lls.org). The blogs we host there (The LLS Blog, @LLS Blog, and Team In Training Blog) serve as the foundation for a communications program which reports on the latest research breakthroughs while it celebrates stories from our community. Just as important, social media gives everyone touched by cancer the opportunity to communicate, share and support one another, because we believe no one should have to fight this disease alone.
The Word from our Patient Services Community We have expanded our social media presence to let LLS patients and their caregivers more readily connect with our many patient support resources.
to display the discussions they prefer, The LLS Blog, The Blood Cancer Our updated Blood Cancer Discussion create their own blog and tag content Discussion Boards, our LLS Facebook Boards make it easier for participants so that others can more readily find Fan Page, and our chat series let patients to read and post messages on a wide pertinent topics. interact candidly about what they’re going range of issues. Several discussion through with others who are going, or threads offer peer-to-peer forums on We now have nearly 2,500 online blood have been, through the same experience topics such as “Waiting for a Diagnosis,” cancer discussions, with more than themselves. They can ask questions about “My Child Has Cancer,” and “Living 7,000 active participants helping hundreds specific treatments, inspire others with With…” discussions of specific blood of patients and their families get the words of encouragement, offer support, cancers. In addition, participants can support they need, because even a few and share the joys as well as the “bumps” now personalize their LLS Community words of encouragement can mean on the road to recovery. homepage (community.lls.org) so much to those battling cancer.
The Leukemia & Lymphoma Society 3
p1-13.indd 3 11/9/10 4:47 PM The Talk from our Fundraising Community What better way to spread the word about our hundreds of fundraising activities than by going directly where most of our donors can be found – ONLINE!
> Gap Give and Get Promotion social media network. In fact, the success LLS was included in three Gap Give of the Gap Promotion provided our first and Get Promotions in fiscal year 2010. insight into the power of fully engaging For 4 days in August and November 2009, our social networking communities. and March 2010, we were given a 30% discount coupon from Gap, with 5% Since the promotion ran for a very of the sales from each customer using limited time, we had to spread the word the coupon going to LLS. Each Gap as quickly and extensively as possible. Promotion featured a patient story and The Gap Promotion was featured on was promoted aggressively through our the @LLS blog and highlighted through
With every support group meeting, with every fundraising event – I’m reminded how powerful my story is and what a source of hope and inspiration it can provide Christen @LLS Blog to others. People thank me all the time for sharing my story because I remind them that ‘Cancer Survivors Have Miracles Too.’ The more I give back, the more I’m aware of the importance of doing so – just like Gap!
Commenting on the importance of the Gap Give and Get Promotion to Benefit The Leukemia & Lymphoma Society
4
p1-13.indd 4 11/9/10 4:47 PM I just read your blog. I am so sorry for your loss. I also lost my mom to non-Hodgkin lymphoma Darelyne 9 years ago. TNT Blog And I am doing the L.A. Rock ‘n’ Roll half marathon in her honor.
Commenting on a Team Nancy post
> Team Nancy Tam Driscoll of Portland, OR had raised funds for LLS’s Team In Training (TNT) for several years. Then, her sister Nancy was diagnosed with an inoperable brain tumor linked to lymphoma and succumbed to the disease in 2009 after a brave six-year battle. “I realized something wonderful about our social networks – our Fan Pages the power of TNT and LLS. I could see on Facebook, our profiles on MySpace, that our actions were helping people and among our LinkedIn Groups on both survive cancer and would someday lead the national and local level. to a cure. I also realized that alone you To enhance their fundraising efforts, In fiscal 2010, our intensive online can race, but together you can really Tam and her sisters created a TNT Team efforts for the Gap Promotion proved make a difference.” Nancy eFundraising page where people successful and helped generate $1.6 Tam persuaded her five other sisters, could make donations online and offer million in donations across the US and who live in North Carolina and Virginia, words of encouragement. The sisters Canada. To date, thanks to the focused to run with her in the Nike Women’s also spread the word through their own fundraising efforts of our friends and Marathon to Benefit The Leukemia social media connections, as did other donors, LLS has received $2.2 million & Lymphoma Society in San Francisco family members and friends. from the Gap Promotion since our and raise $40,000 to honor their initial involvement in 2009, illustrating Their social networking efforts paid beloved sister’s memory. the tremendous power of our online off and Team Nancy is well on its way community. And so Team Nancy was born. to reaching its fundraising goal.
The Leukemia & Lymphoma Society 5
p1-13.indd 5 11/24/10 1:38 PM Congrats! I’m so proud… to be associated with the Iowa Chapter :). I’ve been a volunteer with TNT Iowa since 2003 and continue to do Amanda events with TNT & LTN (Team Dennis). LLS Fan Page The mission of LLS hits close to home. The Iowa Chapter has been a force for good for families throughout the state.
Commenting on the Victory in Iowa post on the LLS Facebook Fan Page
The Dialogue from our Advocacy Community We have used the power of social media to support several state campaigns and coalition-based efforts to pass legislation that will benefit our patients and their families.
> Victory in Iowa One such legislation requires health in trials, as many insurers consider insurance plans to provide routine care these studies to be “experimental” coverage (doctor visits, hospital stays, and therefore won’t extend coverage. x-rays and lab tests) for cancer patients This uncertainty prevents many cancer participating in clinical trials. patients from participating in trials that Clinical trials are a critical s tep could aid in their recovery, and makes in the development of new cancer it difficult for researchers to conduct treatments. However, less than 5 percent the studies that might lead to new of adult cancer patients participate breakthroughs in cancer cures.
6
p1-13.indd 6 11/9/10 4:47 PM It amazes me…
the possibility of cutting these funds George was seriously considered. Cutting funding LLS Fan Page for cancer research & education is unfathomable. Everyone on this site has been personally affected by cancer (self-family-friend). Let’s join together & wrestle this beast to improve survivorship & cure possibilities. Thanks.
Post about “Advocacy Network win the Fight to Retain Blood Cancer Education Program”
The LLS Iowa chapter sprung into action when a bill was proposed the Iowa chapter, including cancer requiring insurance companies to extend survivors Lorna Johns and Dave Hubler, routine medical coverage to patients were on-hand to witness the Governor’s in clinical trials (House File 2075). signature. As Dave said at the ceremony: Using various social media outlets, “I am here today because of clinical the chapter got the word out to patients, trials, after other methods had failed.” family members and volunteers to e-mail their state representatives, urging them People were able to follow this historic to support the bill. day online in real time through updates, photos and video posted on the We’re happy to report that our efforts @LLS Blog, as well as LLS posts on worked. House File 2075 was passed Facebook, Twitter, LinkedIn and Flickr. unanimously in both the Iowa House and Senate and in February 2010, Currently, 32 states and the District Governor Chet Culver signed the bill of Columbia have signed similar bills into law. Several volunteers from into law.
The Leukemia & Lymphoma Society 7
p1-13.indd 7 11/9/10 4:47 PM Advances In Research We use social media to convey the latest news on LLS-funded research, clinical trials, and other breakthroughs in the treatment of blood cancers.
We were also proud to spread the word when Dr. Brian Druker received the prestigious 2009 Lasker- Social media is also a great way to share DeBakey Clinical Medical Research the success of our researchers. For Dr. Kwak was honored for his work in Award for his ground-breaking work example, when LLS-funded researcher developing “personalized” anti-lymphoma with the drug Gleevec®, which greatly Dr. Larry Kwak was named one of the vaccines. He and his research team improves the survival rate for patients World’s 100 Most Influential People recently received a five-year, $6.25 million with chronic myelogenous leukemia by Time Magazine, we celebrated the grant from LLS to extend the promise (CML). LLS has funded Dr. Drucker’s occasion by issuing a blog post and of anti-cancer vaccines to leukemia and work since 1995. Gleevec was approved sharing it with the LLS Community. myeloma as well as lymphoma patients. by the FDA in 2001.
Congratulations Dr. Kwak...
for your good work.
Marilyn Research is key – and always LLS Fan Page looking for better and newer treatments. Look forward to seeing the article and will look for it.
Commenting on the LLS blog post, “LLS-Funded Researcher is on Time Magazine’s List of 100 Most Influential People”
8
p1-13.indd 8 11/9/10 4:47 PM On the following pages are examples Fiscal Year of the progress we made in 2010 in our 2010 Highlights mission to cure blood cancers and improve the quality of life of patients and their families.
Patient Information and Services
> Informational Support Nearly 78,000 inquiries were handled > New Programs In addition, about 2,600 school by Masters-level Information Specialists, We launched YAconnect – Straight personnel, healthcare professionals helping patients navigate the various Talk for Young Adults Facing Cancer, and parents attended the LLS program treatments, clinical trial options a series of programs to help young Welcome Back: Facilitating the School and support services. adults age 18 to 39 deal with “the serious Experience for Childhood Cancer Survivors. and sometimes absurd” sides of cancer. Over 5,060 clinical trial searches were Weekly moderated online chats were conducted using Trial Check, a tool that Community Support > designed for small groups to maximize lists available clinical trials by specific LLS chapters offered 531 family information sharing among participants. blood cancer. Trial Check was created support groups across the US and in partnership with the Coalition Canada. Chapter staff and volunteers LLS launched Navigating Employment of Cancer Cooperative Groups. strengthened their existing relationships and Insurance, the first of three YAconnect and established new ones with more Web casts, featuring an interactive panel Financial Support > than 636 community-based organizations of professionals and young adult cancer More than $14 million was awarded serving Latino/Hispanic, African-American, survivors. through the LLS Co-Pay Assistance rural, and other underrepresented Program to help patients with cancer patients. prescription drug co-pays and insurance premium obligations. In all, 32,833 cancer patients and caregivers participated in 479 activities > Educational Support and programs, made possible by the outreach and collaborative efforts Over 438,000 patients, caregivers of LLS chapters to underrepresented and healthcare professionals attended groups across the US and Canada. LLS national telephone/web blood cancer education programs, and nearly In addition, we’re proud to report 55,000 participants attended community- that 5,376 First Connection matches based LLS chapter blood cancer were made between patients, their family education programs. members and trained peer volunteers.
“YAconnect (www.lls.org/yaconnect) is…a great service for young adults navigating the whole ‘cancer thing’. So nice to see that our age group isn’t forgotten. I know that I will rely on some of the resources provided…as I make the transition from full-time graduate student to jobseeker.”
›› YAconnect webcast participant
The Leukemia & Lymphoma Society 9
p1-13.indd 9 11/9/10 4:47 PM Fiscal Year 2010 Highlights
Research
Our second recipient, Brian J. Druker, M.D. , first received LLS funding in 1995 that was instrumental in the development of Gleevec as a frontline treatment for patients with chronic myelogenous leukemia (CML). The Druker team continues to develop new targeted therapies, diagnostic tests that can identify which new drug might work best for John C. Byrd, M.D. Brian J. Druker, M.D. each patient, and novel clinical trial designs that allow individual patients to receive therapies that best match their disease.
> Biotech Alliance Partnerships > Grants & Awards LLS partners directly with biotechnology LLS continues to support the companies to shorten the timeline for development of breakthrough cancer identifying potential new cancer therapies therapies, committing substantial funding and advance them through the FDA to researchers throughout the world. drug approval process. This fiscal year, This fiscal year, we reviewed 521 grant we forged four new biotech company applications and granted 99 new awards, alliances: including 66 for Career Development and 31 for Translational Research. Avila > LLS is providing up to $3.2 million for the clinical development Two grants were also given through our of AVL-292 to treat adults with B-cell Specialized Center of Research (SCOR) cancers. The drug entered a clinical trial initiative, which has provided over $210 in September 2010. million in grants since its inception in 2000. Both recipients have long-time FORMA Therapeutics > LLS is partnering connections to LLS. John C. Byrd, M.D. , with FORMA to develop small molecule who first received a grant from LLS compounds to inhibit Bcl-6, a key in 2001, is targeting molecular processes lymphoma drug target. Approximately that allow cancers to evolve and survive 85 percent of non-Hodgkin lymphomas today’s standard therapies. originate from B cells.
10
p1-13.indd 10 11/9/10 4:47 PM LLS Therapy Pipeline: Advancing Therapies through Biotech Partnerships
Available to Patients
Phase III Inhibitor Definitive Trial of P13K/PLK
Novel Phase II Liposome- Human Efficacy based Drug Delivery
Antisense Engineered Repurposed BTK Inhibitor Immuno- Drug Inhibitor Clinical Trials Phase I Human Safety therapy for Novel Indication
Epstein HDAC Preclinical Barr Inhibitor Laboratory Testing Bcl-6 Virus Inhibitor Vaccine
Lymphoma Lymphoma Cutaneous Lymphoma Lymphoma Acute Leukemia & AML MDS DLBCL PTLD T-Cell CLL / FL CLL Leukemia Lymphoma Lymphoma
> Progress in Clinical Trials Onconova > LLS is providing LLS continues to make progress up to $10 million in funding in existing programs with our biotech to support the clinical advancement alliance partners. Celator Pharmaceuticals of ESTYBONTM to treat patients reported promising results in their phase with high-risk myelodysplastic 2 clinical trial of CPX-351 for older syndrome (MDS). patients with acute myelogenous leukemia (AML), with an impressive 68 percent Shape Pharmaceuticals > LLS of patients achieving complete response. is providing up to $3.3 million for the clinical development of SHP-141, Our alliance partner, Memgen, reported We have also helped advance the drug a first-in-class topical histone complete response and durable remission Ciclopirox Olamine into a phase 1 deacetylase inhibitor to treat both for a third of patients in their phase 1 clinical clinical trial to further its development early-and late-stage cutaneous T-Cell trial of ISF35 for the treatment of chronic in the treatment of acute myelogenous lymphoma (CTCL). lymphocytic leukemia (CLL). leukemia (AML).
The Leukemia & Lymphoma Society 11
p1-13.indd 11 11/9/10 4:47 PM Fiscal Year 2010 Highlights
> Man & Woman of the Year www.mwoy.org This spirited campaign brings together an incredible group of dynamic Fundraising community leaders with the single goal of raising as much money as possible in 10 weeks to benefit LLS’s mission. This San Diego Marathon since its inception year, the campaign grew to new heights, ® > Team In Training in 1998. This year, we brought over with 650 honored candidates participating
www.teamintraining.org 4,000 participants who raised nearly in 58 campaigns around the country – We are proud to announce that Team $12 million to help find cures including 9 new campaigns. All candidates In Training (TNT) has reached an for blood cancers. who confirmed their participation amazing milestone, raising $1 billion by February 12th were formally thanked In addition, our goal this year has been through national and local sports in a full-page USA Today advertisement. to re-engage TNT alumni as higher level events since its inception in 1988. volunteers, assisting them in identifying As part of our fundraising strategy, TNT formalized it s longstanding and securing corporate teams to we emphasized that candidates actively partnership with Competitor Group Inc. participate with TNT at the national engage their campaign teams through (CGI), organizers of the Rock ‘n’ Roll or local level. We also encouraged alumni all elements of their fundraising plan. Series events. TNT was designated to serve as fundraising coaches to help Our 2010 National Man & Woman as the exclusive charity of the renamed TNT participants – especially first-timers of the Year are a testament to this strategy. Rock ‘n’ Roll San Diego Marathon & – succeed in their fundraising efforts and Man of the Year Bob Mills and Woman 1/2 Marathon to Benefit The Leukemia physical training. This proactive approach of the Year Janice Bender had their & Lymphoma Society. The half marathon to alumni re-engagement has not only campaign teams send out letters to was added to encourage even more introduced new individual, group and potential donors, make personal donation participants in this premier fundraising corporate sponsors to the program, but requests, plan events and much more. event. TNT has taken part in the has also helped increase overall retention. While Bob and Janice come from different states and professional backgrounds, they both proved the power of teamwork. Together, their campaign teams raised over $500,000. In fact, of the 650 participating candidates, 51 raised enough funds to qualify for the research naming rights incentive.
> School & Youth® Programs www.schoolandyouth.org Nearly a quarter of the nation’s schools participated in LLS School & Youth Programs, where students learn the value of working together to raise funds, increase awareness, and make a difference in the fight against cancer. This year, a successful strategy was the distribution of colorful collection boxes for students to take home and collect spare change – a visible reminder for family members to join in the effort and the fun.
12
p1-13.indd 12 11/9/10 4:47 PM > Light The Night ® Walk www.lightthenight.org Our annual Light The Night Walk raised nearly $39 million in donations, > Legacy & Targeted Giving treatments for this disease. Mr. Kirsch attracting more than 250,000 participants This year, we received more than and an anonymous donor joined LLS in 218 communities across the US $7 million in legacy gifts from and the International Waldenström’s and Canada. individuals. Several new members were Macroglobulinemia Foundation (IWMF) added to The Legacy Circle by naming to fund four research grants to develop We continued to focus on recruiting LLS as a beneficiary in their will, trust, WM cell lines, a critical link in discovering more businesses to participate in life insurance policy, or retirement plan. new and more effective treatments the program.Walking side by side with These generous individuals have for this currently incurable disease. our family and friends teams in 2009, graciously given us permission to list more than 82 National Partners raised The family of Mina Yanney, a 41-year old their names so that their gifts can $6.8 million for LLS research and patient Pennsylvania investment analyst who inspire others to do the same. services programs. Setting the standard, died of lymphoma in 2004, had a different once again, was Burlington Coat In addition, we received several idea for their targeted donation. Mina Factory, our top corporate partner Targeted Giving contributions, which had a strong family network to drive in the Light The Night Walk. This year, will provide much needed support him to treatments at a downtown they set another milestone by raising for LLS research and patient programs. Philadelphia cancer center. Sadly, many more than $2 million for LLS, breaking For example, when California other patients did not and had to drive their previous $1 million mark established entrepreneur Steve Kirsch was diagnosed themselves. In Mina’s honor, his family in 2007. Burlington Coat Factory with a rare blood cancer known as provided funds to help local cancer has raised over $7 million since our Waldenstrom’s macroglobulinemia (WM), patients secure round-trip transportation partnership began in 2002. he turned to LLS to help find new for their treatments.
Advocacy LLS volunteer advocates in our Florida, Iowa, and South Carolina chapters The LLS Advocates Network led coalition efforts to pass state laws (www.lls.org/advocacy) grew significantly ensuring full coverage of routine medical this fiscal year and now numbers nearly care for cancer patients participating 50,000 volunteers. We are working This provision provides a coverage in potentially life-saving clinical trials. to segment our volunteers for more “floor” for state-based insurers, This coverage is now required by 32 targeted participation and effective pre-empting state plans that provide states and the District of Columbia. communications. fewer patient protections, but also We are also advocating on the state allowing the states to exceed this LLS joined forces with other patient level for laws that provide patients greater minimum coverage. advocacy groups to ensure that national access to oral cancer treatments by health care reform includes insurance As this provision will impact every type requiring insurance companies to provide coverage of routine care costs (doctor of insurance, state-based legislation coverage for oral chemotherapy equal visits, hospital stays, x-rays, and lab tests) is more critical than ever for providing to what is covered for intravenous (IV) for patients enrolled in clinical trials. the best patient protections possible. treatments.
The Leukemia & Lymphoma Society 13
p1-13.indd 13 11/9/10 4:47 PM Research Lihua Budde, MD, PhD Fred Hutchinson Cancer Research Center Satarupa Basu, PhD* University of Pennsylvania Gerd Bungartz, PhD Grants Massachusetts General Hospital Uttiya Basu, PhD Immune Disease Institute Dinis Calado, PhD* Immune Disease Institute Michael Begley, PhD Beth Israel Deaconess Medical Center Kenneth Campellone, PhD University of California, Berkeley The Marshall A. Lichtman Cristian Bellodi, PhD* Specialized Center of Research Ronald Levy, MD 8 University of California, San Francisco Pedro Carvalho, PhD The Specialized Center for Research Stanford University Harvard Medical School Program funds multi-disciplinary Micah Benson, PhD research by teams of leading-edge Jonathan Licht, MD Harvard Medical School Lucio Castilla, PhD 14 academic investigators that hastens Northwestern University University of Massachusetts the discovery and development Avinash Bhandoola, MD, PhD Medical School of better treatments for leukemia, School of Medicine lymphoma and myeloma patients. University of Pennsylvania 9 A center is composed of at least Scott Lowe, PhD Asher Chanan-Khan, MD three independent research Cold Spring Harbor Laboratory Anja-Katrin Bielinsky, PhD Health Research Incorporated, programs that are integrated University of Minnesota, Twin Cities Roswell Park Cancer Institute Division and supported by scientific core Beverly S. Mitchell, MD 10 laboratories. Stanford University Susan Biggins, PhD Jing Chen, PhD* Fred Hutchinson Cancer Research Center Emory University Jerry Adams, PhD Stephen Nimer, MD Walter & Eliza Hall Institute Memorial Sloan-Kettering Cancer Center Daniel Billadeau, PhD Wei-Yi Chen, PhD of Medical Research Mayo Clinic and Foundation Rockefeller University Michael Thirman, MD 11 Frederick Alt, PhD The University of Chicago Debabrata Biswas, PhD Xi Chen, PhD Immune Disease Institute Rockefeller University Harvard University School Cheryl Willman, MD of Public Health Jon Aster, MD, PhD University of New Mexico Dale Bixby, MD, PhD Brigham & Women’s Hospital University of Michigan Yi-Bin Chen, MD Massachusetts General Hospital Irwin Bernstein, MD Marie Bleakley, MD 12 Career Development Program Fred Hutchinson Cancer Research Center Fred Hutchinson Cancer Research Center Tao Cheng, MD The Career Development Program University of Pittsburgh John Byrd, MD* 1 provides stipends to investigators Marzenna Blonska, PhD of exceptional promise in the early Ohio State University stages of their careers, helping University of Texas Uhn-Soo Cho, PhD* them devote their careers to M.D. Anderson Cancer Center Harvard Medical School Riccardo Dalla-Favera, MD 2 leukemia, lymphoma and/or Columbia University myeloma research. Michael Boddy, PhD Yoonsu Choi, PhD The Scripps Research Institute University of Texas Brian Druker, MD* Tahamtan Ahmadi, MD, PhD* M.D. Anderson Cancer Center Howard Hughes Medical Institute, University of Pennsylvania Catherine Bollard, MD Oregon Health & Science University Baylor College of Medicine Yuh Min Chook, PhD* Cancer Institute Ioannis Aifantis, PhD University of Texas, New York University School of Medicine Niccolo Bolli, MD Southwestern Medical Center Carolyn Felix, MD 3 Dana-Farber Cancer Institute The Children’s Hospital of Philadelphia Arash Alizadeh, MD, PhD* Eric Chow, MD Stanford University Ivan Borrello, MD Fred Hutchinson Cancer Research Center Anthony Green, MD, PhD 4 Johns Hopkins University University of Cambridge Shannon Anderson, PhD School of Medicine Wen-Ming Chu, MD, PhD University of California, San Francisco Brown University James Griffin, MD5 Marina Bousquet, PhD 13 Dana-Farber Cancer Institute Philippe Armand, MD, PhD Whitehead Institute Elaine Chung, PhD Dana-Farber Cancer Institute for Biomedical Research University of Pennsylvania Helen Heslop, MD Baylor College of Medicine Scott Armstrong, MD, PhD Troy Brady, PhD* Maria Ciofani, PhD Children’s Hospital Boston University of Pennsylvania New York University School of Medicine Carl June, MD University of Pennsylvania Laura Attardi, PhD Andrea Bredemeyer, PhD* Pasquale Cirone, PhD Stanford University Brigham & Women’s Hospital Yale University Thomas Kipps, MD, PhD 6 University of California, San Francisco Cynthia Barber, PhD* Jennifer Brown, MD, PhD* Kenneth Cooke, MD Brandeis University Dana-Farber Cancer Institute Case Western Reserve University Larry Kwak, MD, PhD 7 University of Texas Craig Bassing, PhD* Claudio Brunstein, MD* Naomi Courtemanche, PhD* M.D. Anderson Cancer Center The Children’s Hospital of Philadelphia University of Minnesota, Twin Cities Yale University
1 Dr. John Byrd is funded in part by 4 Dr. Anthony Green is funded in part by 8 Dr. Ronald Levy is funded in part by 11 Dr. Michael Thirman is funded in part by Douglas A. and Phyllis Smith, Elaine an anonymous donor. Guy and Linda Nohra. The Pamela B. Katten Memorial Leukemia Smith and Michael and Jacqueline Thomas. Research Foundation, the Alverin M. Cornell 5 Dr. James Griffin is funded in part by 9 Dr. Scott Lowe is funded in part by Foundation, Paul and Joan Rubschlager 2 Dr. Riccardo Dalla-Favera is funded in part the F.M. Kirby Foundation and the Karyn The Altschul Foundation/Reichman Foundation, the Helen Brach Foundation, by the Paul E. Singer Family Foundation, Research Fund. Memorial. The Dr. Ralph and Marion Falk Medical Joseph S. and Diane H. Steinberg 6 Dr. Thomas Kipps is funded in part by 10 Dr. Beverly S. Mitchell is funded in part by Research Trust, the Kluth Family Charitable Trust, and J.T. Tai & Co. the Silicon Valley Community Foundation the Joseph C. Sanfilippo Memorial Fund and Foundation, Alberto-Culver Company, Foundation. and an anonymous donor. the Harry T. Mangurian, Jr. Foundation, Inc. The Bohnen Family Foundation and 3 Dr. Carolyn Felix is funded in part by the Kenneth and Angela Paulan Fund. 7 Dr. Larry Kwak is funded in part by The Bryce Foundation. Gerry Golub.
14 David Ferguson, MD, PhD Jin He, MD, PhD John Crispino, PhD University of Michigan University of North Carolina Barbara Kee, PhD Northwestern University at Chapel Hill The University of Chicago School of Medicine Adolfo Ferrando, MD, PhD Columbia University Xi He, PhD Younghoon Kee, PhD Vincenzo D’Angiolella, MD, PhD Children’s Hospital Boston Dana-Farber Cancer Institute New York University School of Medicine Maria Figueroa, MD* Weill Medical College Jorge Henao-Mejia, MD, PhD* Karen Keeshan, PhD 18 Louise D’Cruz, PhD of Cornell University Yale University University College Cork University of California, San Diego Noelle Frey, MD Kiersten Henderson, PhD TaeSoo Kim, PhD Monique Dail, PhD University of Pennsylvania Fred Hutchinson Cancer Research Center Harvard Medical School University of California, San Francisco Jonathan Friedberg, MD 16 David Hesslein, PhD Scott Kogan, MD Mari Dallas, MD University of Rochester University of California, San Francisco University of California, San Francisco St. Jude Children’s Research Hospital Maxim Frolov, PhD* Elizabeth Hexner, MD Minoree Kohwi, PhD Blossom Damania, PhD University of Illinois, Chicago University of Pennsylvania University of Oregon University of North Carolina at Chapel Hill Kyriaki Galani, PhD Gilles Hickson, PhD Motonari Kondo, MD, PhD Massachusetts Institute of Technology University of Montreal Duke University Medical Center Michael Davis, PhD Fred Hutchinson Cancer Research Center Boyi Gan, PhD Angela Hilliker, PhD Mei Kong, PhD Dana-Farber Cancer Institute University of Arizona University of Pennsylvania Renee de Pooter, PhD University of Oxford Neil Ganem, PhD Heedeok Hong, PhD Rhett Kovall, PhD Dana-Farber Cancer Institute University of California, Los Angeles University of Cincinnati Michael Deininger, MD, PhD Oregon Health & Science University Jason Garrison, PhD Jian Hu, PhD Maxwell Krem, MD, PhD* Burnham Institute for Medical Research Dana-Farber Cancer Institute University of Washington Ludovic Deriano, PhD New York University School of Medicine Ulrike Gerdemann, MD* Jian Huang, MD, PhD Matthew Krummel, PhD Baylor College of Medicine University of Pennsylvania University of California, San Francisco Luisa Di Stefano, PhD Massachusetts General Hospital Benjamin Gewurz, MD, PhD Yun Huang, PhD* Mijung Kwon, PhD Brigham & Women’s Hospital Immune Disease Institute. Dana-Farber Cancer Institute J. Alan Diehl, PhD University of Pennsylvania Nilanjan Ghosh, MD, PhD* Michael Hudecek, MD* James LaBelle, MD, PhD* Johns Hopkins University Fred Hutchinson Cancer Research Center Dana-Farber Cancer Institute Chen Dong, PhD School of Medicine University of Texas Madhulika Jain, PhD Adam Lazorchak, PhD M.D. Anderson Cancer Center Florent Ginhoux, PhD Harvard Medical School Yale University Singapore Immunology Network Gregory Driessens, PhD Robert Jenq, MD Sang Eun Lee, PhD The University of Chicago Ajay Gopal, MD Memorial Sloan-Kettering Cancer Center University of Texas University of Washington M.D. Anderson Cancer Center Jarrod Dudakov, PhD* Peng Ji, MD, PhD Sloan-Kettering Institute Daniel Gough, PhD* Whitehead Institute Francene Lemoine, PhD New York University School of Medicine for Biomedical Research Northwestern State University Mary Eapen, MBBS of Louisiana Medical College of Wisconsin Daniel Graham, PhD Emma Josefsson, PhD Washington University in St. Louis Walter & Eliza Hall Institute Gustavo Leone, PhD Nicholas Endres, PhD of Medical Research Ohio State University University of California, Berkeley H. Leighton Grimes, PhD Cincinnati Children’s Hospital Przemyslaw Juszczynski, MD, PhD Anthony Letai, MD, PhD 19 Kolja Eppert, PhD 15 Medical Center Dana-Farber Cancer Institute Dana-Farber Cancer Institute University Health Network Allan Gurtan, PhD Axel Kallies, PhD Anthony Leung, PhD Michael Farrar, PhD Massachusetts Institute of Technology Walter & Eliza Hall Institute Massachusetts Institute of Technology University of Minnesota, Twin Cities of Medical Research Sara Hamilton, PhD Mark Levis, MD, PhD 20 Niklas Feldhahn, PhD University of Minnesota, Twin Cities Sumin Kang, PhD Johns Hopkins University Rockefeller University Emory University School of Medicine Omid Harandi, PhD* David Feldser, PhD University of Massachusetts Tarun Kapoor, PhD 17 Erin Lew, PhD Massachusetts Institute of Technology Medical School Rockefeller University The Salk Institute for Biological Studies
Suhua Feng, PhD* Danna Hargett, PhD David Kashatus, PhD Zachary Lewis, PhD University of California, Los Angeles Princeton University Duke University Medical Center University of Oregon
12 Dr. Marie Bleakley is funded in part by 15 Dr. Kolja Eppert, a Stephen Birnbaum 17 Dr. Tarun Kapoor is funded in part by * Newly awarded or renewed grants the Douglas Kroll Research Foundation. Scholar, is fully funded by The Stephen The Robert H. Lyon Leukemia Foundation. in fiscal year 2011 Birnbaum Foundation. 13 Dr. Marina Bousquet is fully funded by 18 Dr. Karen Keeshan, a Stephen Birnbaum Gertrude B. Elion Research Fund. 16 Dr. Jonathan Friedberg, a Millennium: Scholar, is fully funded by The Stephen 20 The Takeda Oncology Company Scholar, Birnbaum Foundation. Dr. Mark Levis is funded in part by 14 Dr. Lucio Castilla is funded in part by is fully funded by Millennium: The Takeda the Douglas Kroll Research Foundation The Robert H. Lyon Leukemia Foundation 19 Dr. Anthony Letai, a Millennium: The Oncology Company. and the Rally Foundation for Childhood and the Remillard Family Foundation. Takeda Oncology Company Scholar, is fully Cancer Research. funded by Millennium: The Takeda Oncology Company.
The Leukemia & Lymphoma Society 15 Anand Ranjan, PhD Research Jeffrey Nolz, PhD National Cancer Institute The University of Iowa Jeffrey Rathmell, PhD Kristi Norris, PhD* Duke University Medical Center Grants Continued Duke University Medical Center Pavan Reddy, MD* Leta Nutt, PhD University of Michigan St. Jude Children’s Research Hospital Boris Reizis, PhD* Christopher Oakes, PhD Columbia University Deutsches Krebsforschungszentrum (German Cancer Research Center) Linda Resar, MD 25 Shaoguang Li, MD, PhD Johns Hopkins University Daniel Marston, PhD University of Massachusetts Philipp Oberdoerffer, PhD School of Medicine Medical School University of North Carolina Harvard Medical School at Chapel Hill Ran Reshef, MD* Willis Li, PhD Robert Orlowski, MD, PhD University of Pennsylvania University of Rochester Peter Martin, MD University of Texas Weill Medical College M.D. Anderson Cancer Center Andrey Revyakin, PhD Zejuan Li, MD, PhD* of Cornell University University of California, Berkeley The University of Chicago Kostandin Pajcini, PhD* William Matsui, MD University of Pennsylvania Tannishtha Reya, PhD 26 Zihai Li, MD, PhD Johns Hopkins University Duke University Medical Center University of Connecticut School of Medicine Jing Pan, PhD Memorial Sloan-Kettering Cancer Center Robin Ricke, PhD Chengyu Liang, MD, PhD David Matus, PhD* Mayo Clinic and Foundation University of Southern California Duke University Qishen Pang, PhD 23 Cincinnati Children’s Hospital David Rizzieri, MD Sergiy Libert, PhD Alexander Mazin, PhD Medical Center Duke University Medical Center Massachusetts Institute of Technology Drexel University Medical Center Dongsu Park, PhD Edward Rogers, PhD Weei-Chin Lin, MD, PhD Ari Melnick, MD Massachusetts General Hospital University of North Carolina University of Alabama at Birmingham Weill Medical College at Chapel Hill of Cornell University Danilo Perrotti, MD, PhD 24 Xin Lin, PhD 21 Ohio State University Theodora Ross, MD, PhD University of Texas Joshua Mendell, MD, PhD University of Michigan M.D. Anderson Cancer Center Johns Hopkins University John Perry, PhD School of Medicine Stowers Institute for Medical Research Giovanni Roti, MD* Allen Liu, PhD Dana-Farber Cancer Institute The Scripps Research Institute Nam-Sung Moon, PhD Daniel Pollyea, MD* McGill University Stanford University Monideepa Roy, PhD Ling Liu, PhD Brigham & Women’s Hospital Stanford University Stefanie Mortimer, PhD* Christos Polytarchou, PhD University of California, Berkeley New England Medical Center James Rubenstein, MD, PhD Mignon Loh, MD Hospitals, Inc. University of California, San Francisco University of California, San Francisco Britta Mueller, PhD* Massachusetts General Hospital Martin Prlic, PhD Loredana Ruggeri, MD, PhD* Simonne Longerich, PhD University of Washington University of Perugia Yale University James Mulloy, PhD* Cincinnati Childrens Hospital Philippe Prochasson, PhD Davide Ruggero, PhD* Sonja Lorenz, PhD* Medical Center University of Kansas Medical Center University of California, San Francisco University of California, Berkeley Andrew Mungall, PhD Thomas Pucadyil, PhD Laurent Sabbagh, PhD Li-Fan Lu, PhD BC Cancer Agency/British Columbia The Scripps Research Institute University of Toronto Memorial Sloan-Kettering Cancer Center Cancer Agency Marc Raaijmakers, MD, PhD Julien Sage, PhD Shuo Ma, MD, PhD Markus Muschen, MD* Massachusetts General Hospital Stanford University Northwestern University Childrens Hospital Los Angeles School of Medicine Gunnar Ragnarsson, MD Sandrine Sander, MD, PhD* Anita Nag, PhD Fred Hutchinson Cancer Research Center Immune Disease Institute. Hiten Madhani, MD, PhD Yale University University of California, San Francisco Noopur Raje, MD Karsten Sauer, PhD* Shalin Naik, PhD* Massachusetts General Hospital The Scripps Research Institute Sebastien Malinge, PhD The Netherlands Cancer Institute Northwestern University Rajesh Ramachandran, PhD Aaron Schimmer, MD, PhD School of Medicine Shima Nakanishi, PhD The Scripps Research Institute University Health Network Stowers Institute for Medical Research Aron Marquitz, PhD Dale Ramsden, PhD Stephen Schoenberger, PhD University of North Carolina Geeta Narlikar, PhD 22 University of North Carolina La Jolla Institute for Allergy at Chapel Hill University of California, San Francisco at Chapel Hill and Immunology
21 Dr. Xin Lin is funded in part by 22 Dr. Geeta Narlikar is funded in part by 23 Dr. Qishen Pang is funded in part by 25 Dr. Linda Resar is funded in part by an anonymous donor. Walter and Beth Grant. The Marge & Charles J. Schott Foundation. the Cora and John H. Davis Foundation.
24 Dr. Danilo Perrotti is funded in part by 26 Dr. Tannishtha Reya, a Ryan Gibson Charles and Lynda Kraemer and Mark Foundation Scholar, is partly funded by and Christine Kraemer. The Ryan Gibson Foundation.
16 Ivan Topisirovic, MD, PhD McGill University Jianchang Yang, MD, PhD Pamela Becker, MD, PhD 33 Baerbel Schroefelbauer, PhD* Nevada Cancer Institute University of Washington University of California, San Diego Jennifer Trowbridge, PhD Dana-Farber Cancer Institute Tingting Yao, PhD Linda Bendall, PhD Suzanne Schubbert, PhD 27 Colorado State University University of Sydney University of California, Los Angeles Hsin-yue Tsai, PhD University of Massachusetts Tong Yin, MD, PhD Ravi Bhatia, MD Ralph Scully, MD, PhD Medical School Stowers Institute for Medical Research City of Hope National Medical Center Beth Israel Deaconess Medical Center Cameron Turtle, MBBS, PhD* Carol Ying, PhD Smita Bhatia, MD 34 Rosalie Sears, PhD Fred Hutchinson Cancer Research Center Columbia University City of Hope National Medical Center Oregon Health & Science University Katharine Ullman, PhD Hoi-Ying (Elsie) Yu, PhD Helen Blau, PhD Camile Semighini, PhD University of Utah Brandeis University Stanford University Duke University Medical Center Lidia Vasilieva, PhD Rushdia Yusuf, MD* Bruce Blazar, MD Neil Shah, MD, PhD 28 Oxford University Massachusetts General Hospital University of Minnesota, Twin Cities University of California, San Francisco Shobha Vasudevan, PhD Shan Zha, MD, PhD Katherine Borden, PhD* Smita Shankar, PhD Massachusetts General Hospital Children’s Hospital Boston Universite de Montreal University of California, San Francisco Suzanne Vercauteren, MD, PhD Baochun Zhang, MD, PhD Carl Borrebaeck, PhD* Sonia Sharma, PhD University of British Columbia Immune Disease Institute Lund University Immune Disease Institute Dan Vogl, MD Ji Zhang, PhD* Kevin Brindle, PhD Wei-Jong Shia, PhD 29 University of Pennsylvania University of Pennsylvania University of Cambridge University of California, San Diego Johannes Walter, PhD Weiguo Zhang, PhD John Byrd, MD 35 Warren Shlomchik, MD 30 Harvard Medical School Duke University Medical Center Ohio State University Yale University Demin Wang, PhD Yanping Zhang, PhD Nicola Camp, PhD Erika Shor, PhD Blood Research Institute University of North Carolina University of Utah Princeton University at Chapel Hill Gang (Greg) Wang, PhD Asher Chanan-Khan, MD Peter Sicinski, MD, PhD Rockefeller University Yu Zhang, PhD Health Research Incorporated, Dana-Farber Cancer Institute Memorial Sloan-Kettering Cancer Center Roswell Park Cancer Institute Division Lan Wang, PhD* Robert Signer, PhD* Memorial Sloan-Kettering Cancer Center Zhiguo Zhang, PhD Preet Chaudhary, MD, PhD University of Michigan Mayo Clinic and Foundation University of Pittsburgh Mitchell Weiss, MD, PhD Jane Skok, PhD* The Children’s Hospital of Philadelphia Pengbo Zhou, PhD Suning Chen, PhD* New York University School of Medicine Weill Medical College Jiangsu Institute of Hematology, John Welch, MD, PhD of Cornell University Soochow University Catherine Smith, MD* Washington University in St. Louis University of California, San Francisco Rui Zhou, PhD Wei Chen, MD, PhD William Wierda, MD, PhD 31 Harvard Medical School University of Minnesota, Twin Cities Zhou Songyang, PhD University of Texas Baylor College of Medicine M.D. Anderson Cancer Center Yubin Zhou, PhD Selina Chen-Kiang, PhD* 36 Immune Disease Institute Weill Medical College Tracy Staton, PhD Sarah Wignall, PhD of Cornell University Harvard University Stanford University Dimitrios Zisoulis, PhD* School of Public Health University of California, San Diego Kent Christopherson, PhD Jeremy Wilusz, PhD* Rush University Medical Center Milan Stojanovic, PhD Massachusetts Institute of Technology Columbia University Translational Research Program Curt Civin, MD Petter Woll, PhD University of Maryland The Translational Research Travis Stracker, PhD University of Oxford School of Medicine Program supports outstanding Institute for Research in Biomedicine investigations deemed by our expert Jamie Wood, PhD* advisors most likely to translate Michael Cleary, MD Matthew Strout, MD, PhD University of Minnesota, Twin Cities basic biomedical discoveries into Stanford University Yale University new, safe and effective treatments, Tao Wu, PhD ultimately prolonging and enhancing Christopher Cogle, MD Jason Stumpff, PhD* Harvard Medical School patients’ lives. University of Florida University of Washington Huafeng Xie, PhD Albert Baldwin, PhD John Crispino, PhD Kelly Sullivan, PhD* Dana-Farber Cancer Institute University of North Carolina Northwestern University University Of Colorado at Chapel Hill School of Medicine Ming Xu, PhD 32 Wojciech Swat, PhD University of Texas Julio Barredo, MD Alan D’Andrea, MD 37 Washington University in St. Louis Southwestern Medical Center at Dallas University of Miami School of Medicine Dana-Farber Cancer Institute
27 Dr. Suzanne Schubbert is funded in part 31 Dr. William Wierda is funded in part by 34 Dr. Smita Bhatia is funded in part by Mike * Newly awarded or renewed grants by Parents Against Leukemia. Michelle Henkel, the Silicon Valley and Claire Shevlin – Links For Leukemia. in fiscal year 2011 Community Foundation and an 28 Dr. Neil Shah is fully funded by 35 Dr. John Byrd is funded in part by anonymous donor. the Estate of Virginia Hoffman. The Bob Cooper CLL Research Fund, 37 Dr. Alan D’Andrea is funded in part by 32 Dr. Ming Xu is fully funded by the Dallas the Silicon Valley Community Foundation 29 Dr. Wei-Jong Shia, a Stephen Birnbaum Saint Valentine’s Luncheon and Fashion and an anonymous donor. The Robert H. Lyon Leukemia Foundation. Scholar, is fully funded by The Stephen Show. Birnbaum Foundation. 36 Dr. Selina Chen-Kiang is funded in part by 33 Dr. Pamela Becker is funded in part by the Dallas Saint Valentine’s Luncheon and 30 Dr. Warren Shlomchik is fully funded by the Douglas Kroll Research Foundation. Fashion Show in memory of Lynda Adleta. The Newman Family.
The Leukemia & Lymphoma Society 17 Research
Grants Continued Daniel Link, MD Washington University in St. Louis
Hsiou-Chi Liou, PhD Weill Medical College of Cornell University Felipe Samaniego, MD* 47 University of Texas George Daley, MD, PhD Mignon Loh, MD M.D. Anderson Cancer Center Brigham & Women’s Hospital Irene Ghobrial, MD University of California, San Francisco Dana-Farber Cancer Institute Barbara Savoldo, MD, PhD Chi Dang, MD, PhD Lawrence Lum, MD, DSC Baylor College of Medicine Johns Hopkins University Steven Grant, MD 40 Wayne State University School of Medicine Virginia Commonwealth University Aaron Schimmer, MD, PhD Nadim Mahmud, MD, PhD University Health Network Utpal Dave, MD Jolanta Grembecka, PhD University of Illinois, Chicago Vanderbilt University University of Michigan Motomu Shimaoka, MD, PhD Ari Melnick, MD 44 Immune Disease Institute James DeGregori, PhD Monica Guzman, PhD 41 Weill Medical College University of Colorado at Denver Weill Medical College of Cornell University Margaret Shipp, MD of Cornell University Dana-Farber Cancer Institute Gerald Denis, PhD David Miklos, MD, PhD* Trustees of Boston University Lori Hazlehurst, PhD Stanford University Alexander Stewart, MD H. Lee Moffitt Cancer Center Mayo Clinic and Foundation Madhav Dhodapkar, MD & Research Institute Markus Muschen, MD 45 Yale University Children’s Hospital Los Angeles Samuel Strober, MD Laurence Hurley, PhD, DSC Stanford University Dirk Dittmer, PhD* University of Arizona Owen O’Connor, MD, PhD University of North Carolina New York University School of Medicine John Timmerman, MD Chapel Hill Craig Jordan, PhD* 42 University of California, Los Angeles University of Rochester Vivian Oehler, MD Gianpietro Dotti, MD* Fred Hutchinson Cancer Research Center Amit Verma, MD Baylor College of Medicine Richard Jones, MD Albert Einstein College of Medicine Johns Hopkins University Robert Orlowski, MD, PhD* Dimitar Efremov, MD, PhD* School of Medicine University of Texas Mariusz Wasik, MD International Centre for Genetic M.D. Anderson Cancer Center University of Pennsylvania Engineering and Biotechnology Scott Kaufmann, MD, PhD Mayo Clinic and Foundation Leonidas Platanias, MD, PhD Deborah White, PhD Elizabeth Eklund, MD Northwestern University Institute of Medical and Northwestern University Scott Kaufmann, MD, PhD School of Medicine Veterinary Science School of Medicine Mayo Clinic and Foundation Josef Prchal, MD Joseph Wiemels, PhD Thomas Diacovo, MD Tomas Kirchhoff, PhD University of Utah University of California, San Francisco Columbia University Memorial Sloan-Kettering Cancer Center Miles Prince, MD Catherine Wu, MD 48 Martin Fernandez-Zapico, MD Susan Knox, MD, PhD 43 University of Melbourne Dana-Farber Cancer Institute Mayo Clinic and Foundation Stanford University Lee Ratner, MD, PhD Mingjiang Xu, MD, PhD Adolfo Ferrando, MD, PhD 38 Jeanne Kowalski, PhD Washington University in St. Louis Mount Sinai School of Medicine Columbia University Johns Hopkins University School of Medicine Pavan Reddy, MD B. Hilda Ye, PhD James Ferrara, MD University of Michigan Albert Einstein College of Medicine University of Michigan Donald Kufe, MD Dana-Farber Cancer Institute Robert Redner, MD Qing Yi, MD, PhD Christopher Flowers, MD* University of Pittsburgh University of Texas Emory University Wen-Hwa Lee, PhD M.D. Anderson Cancer Center University of California, Irvine Susan Rheingold, MD Richard Ford, MD, PhD The Children’s Hospital of Philadelphia Andrew Zannettino, PhD University of Texas Suzanne Lentzsch, MD, PhD Institute of Medical and M.D. Anderson Cancer Center University of Pittsburgh Alain Rook, MD Veterinary Science University of Pennsylvania Mark Frattini, MD, PhD Ross Levine, MD Muxiang Zhou, MD Memorial Sloan-Kettering Cancer Center Memorial Sloan-Kettering Cancer Center Joseph Rosenblatt, MD Emory University University of Miami Celine Gelinas, PhD 39 Shaoguang Li, MD, PhD Patrick Zweidler-McKay, MD, PhD UMDNJ -- Robert Wood Johnson University of Massachusetts Janet Rowley, MD 46 University of Texas Medical School School of Medicine The University of Chicago M.D. Anderson Cancer Center
38 Dr. Adolfo Ferrando is funded in part by 40 Dr. Steven Grant is funded in part by 44 Dr. Ari Melnick, a Quest Diagnostics, Inc. * Newly awarded or renewed grants Eli Lilly and Company and the Rally The Breeden-Adams Foundation. Translational Researcher, is fully funded by in fiscal year 2011 Foundation for Childhood Cancer Research. Quest Diagnostics, Inc. 41 Dr. Monica Guzman is funded in part by 39 Dr. Celine Gelinas is funded in part by Robert and JoAnna Behl. 45 Dr. Markus Muschen is funded in part by 47 Guy Chiarello and Guy Del Grande. the California Community Foundation. Dr. Felipe Samaniego is funded in part by 42 Dr. Craig Jordan is funded in part by an anonymous donor. the Douglas Kroll Research Foundation. 46 Dr. Janet Rowley is funded in part by 48 The Pamela B. Katten Memorial Leukemia Dr. Catherine Wu is funded in part by 43 Dr. Susan Knox is funded in part by Research Foundation and the Dr. Scholl the Silicon Valley Community Foundation The Valley Foundation. Foundation. and an anonymous donor.
18 Research Portfolios
LLS Research Portfolios are groups of research projects organized around 1 Acute Lymphocytic Leukemia Research Portfolio is funded in part by Deborah Flanagan a specific blood cancer interest. Following is a list of the available portfolios – Translational Research Program and David and Kim Savage – Megan’s Wings, Inc. and the donors who generously provided support during this fiscal year 2 Acute Myeloid Leukemia and Myelodysplastic Syndromes Research Portfolio is funded in part by Ann Adams, Hildegarde D. Becher Foundation, Inc., The For Julie Foundation, Inc., King & Spalding, LLP, Neil Kishter, Peter and Tina Locke, The Robert H. Lyon Leukemia Foundation, Acute Lymphocytic Leukemia 1 Clyde Smith McGregor – In Memory of Joan Kowing McGregor, Poster Family Foundation, Acute Myeloid Leukemia and Myelodysplastic Syndromes 2 Francis X. and Susan Reinhardt, Jeff and Pat Sachs, The Shimkin Foundation, Technology Concepts & Design, Inc. and the Westchester Tri Team. Chronic Lymphocytic Leukemia 3 3 Chronic Lymphocytic Leukemia Research Portfolio is funded in part by the American Chronic Myelogenous Leukemia 4 Construction Co., Inc., Helen Anbinder, Stephen and Madeline Anbinder, Brian and Lisa Bee – Spin 4 the Cure, Imagine a Cure for Leukemia, The Jim Jacobs Charitable Foundation, Hodgkin Lymphoma 5 Marlene and Andrew Lippmann and an anonymous donor. Mantle Cell Lymphoma 6 4 Chronic Myelogenous Leukemia Research Portfolio is funded in part by Rick and Debby Cox, Myeloma 7 The Ryan Gibson Foundation, Imagine a Cure for Leukemia, Larry and Leslie Nance and James and Judith Wilson. Aggressive Non-Hodgkin Lymphoma 8 5 Hodgkin Lymphoma Research Portfolio is funded in part by Ron and Rosie Kilpatrick. Indolent Non-Hodgkin Lymphoma 9 6 Mantle Cell Lymphoma Research Portfolio is funded in part by Frank Sunberg. Pediatric and Young Adult Blood Cancers 10 7 Myeloma Research Portfolio is funded in part by the Carlson Family Foundation, Quality of Life 11 Names Family Foundation and the New York State Union of Teachers.
Therapy Acceleration Program 12 8 Aggressive Non-Hodgkin Lymphoma Research Portfolio is funded in part by Creative Escape/ Bazzill Basics Paper, the J.B. Fuqua Foundation, Headstrong Foundation, Poster Family Waldenstrom Macroglobulinemia Initiative 13 Foundation and The Doug Steele Family – Doug Steele Golf Fore Life Tournament.
9 Indolent Non-Hodgkin Lymphoma Research Portfolio is funded in part by The Jim Jacobs Charitable Foundation, Timothy and Christine Lindenfelser, Jerry and Lois Rosenblum and an anonymous donor.
10 Pediatric and Young Adult Blood Cancer Research Portfolio is funded in part by Brian and Lisa Bee – Spin 4 the Cure, Thomas and Agnes Carvel Foundation, The Jeff Gordon Foundation, Karyn Research Fund, the Michael W. McCarthy Foundation, Phoenix Partners Group, The Regence Group – In honor of Steven Hooker, Melissa Segal and Wawa.
11 Quality of Life Research Portfolio is funded in part by the Hildegarde D. Becher Foundation, Danford Foundation, The Escher Foundation, Greg and Michelle Becker, Mike and Kathy Ladra, Hamill Family Trust, McKesson Corporation Foundation, Inc. – In memory of Daniel Berkey, Edward Miner, Ping Y. Tai Foundation, Inc. and an anonymous donor.
12 Therapy Acceleration Program is funded in part by Bruce Bocina, the Peter Burg Memorial Research Fund, The For Julie Foundation, Inc., Frederick and Rosemary Goodwin, John Kellenyi, Patrick and Nancy Minan, Jerry and Lois Rosenblum, The William J. Shaw Family Foundation and Team Timko.
13 Waldenstrom Macroglobulinemia Initiative is fully funded by Peter Bing, International Waldenstrom Macroglobulinemia Foundation and the Steven and Michele Kirsch Fund, an advised fund of the Silicon Valley Community Foundation.
The Leukemia & Lymphoma Society 19 Professional Education Medical & Scientific Subcommittee
Advisors Chair Irwin Bernstein, MD Fred Hutchinson Cancer Research Center
Chair Armand Keating, MD Selina Chen-Kiang, PhD Princess Margaret Hospital Weill Medical College of Cornell University Vice Chair Margaret Shipp, MD Brian Druker, MD Dana-Farber Cancer Institute Howard Hughes Medical Institute, Oregon Health & Science University Cancer Institute
Frederick Appelbaum, MD James Griffin, MD Fred Hutchinson Cancer Research Center Dana-Farber Cancer Institute
Irwin Bernstein, MD Judith Karp, MD Fred Hutchinson Cancer Research Center Johns Hopkins Medical Institute
Alexandra Mayes Birnbaum Armand Keating, MD Peartree Publishing Princess Margaret Hospital
Selina Chen-Kiang, PhD Beverly S. Mitchell, MD Weill Medical College Stanford University of Cornell University Cancer Research Center
Curt I. Civin, MD Warren S. Pear, MD, PhD University of Maryland University of Pennsylvania School of Medicine Abramson Family Cancer Research Institute Jorge Cortes, MD The University of Texas, M.D. Anderson Cancer Center
Brian Druker, MD Howard Hughes Medical Institute, Oregon Health & Science University Cancer Institute Endowment Alan Gewirtz, MD University of Pennsylvania, School of Medicine Funds D. Gary Gilliland, MD, PhD Merck & Co., Inc.
James Griffin, MD Dana-Farber Cancer Institute
Mary Horowitz, MD The Bill Beattie Memorial Medical College of Wisconsin Endowment Fund (Alberta) Mary & Robert Bronstein Memorial Fund Catriona Jamieson, MD, PhD University of California, San Diego The Virginia Major Brooks Memorial Endowment Fund Judith Karp, MD de Villiers Endowment Fund Johns Hopkins Medical Institute Thomas M. Ford Memorial Fund Beverly S. Mitchell, MD Stanford University GlaxoSmithKline Foundation and Cancer Research Center GlaxoSmithKline, Inc. Research Fund Jim Jacobs Leukemia Research Fund Warren S. Pear, MD, PhD University of Pennsylvania The Rachel Kudish Fund Abramson Family Jane Elissa/Charlotte Meyers Cancer Research Institute Endowment Fund Nancy Speck, PhD The Rae Endowment Fund (Ontario) University of Pennsylvania, School of Medicine Vrushali Ranadive Fellowship Fund Reich Endowment Fund Guido Tricot, MD, PhD University of Utah, School of Medicine The UFCW (Canada) Endowment Fund
20 Donors
$50,000 – $99,999 The below listing is made up DialAmerica 99.1 KGGI of individuals, foundations and corporations that generously Elbit Systems of America, LLC Accenture supported LLS’s mission during Lunardi’s Markets this fiscal year. Enzon Pharmaceuticals, Inc. Air Products Michael W. McCarthy Foundation Deborah Flanagan* Alion Science & Technology $1,000,000 and Above James and Patricia McPherson GlaxoSmithKline Allos Therapeutics, Inc. Burlington Coat Factory Microsoft Corporation The Jeff Gordon Foundation American Airlines Celgene Corporation Mills Family Foundation The Greene Team American Electric Power Centers for Disease Control The Offterdinger Family and Prevention* Estate of Virginia Hoffman AMERICAN SYSTEMS PhRMA The Gap Foundation Imagine a Cure for Leukemia Baker Tilly PricewaterhouseCoopers LLP Genentech, Inc. International Waldenstrom’s Barclays Capital Macroglobulinemia Foundation* Regence BlueCross BlueShield* KGO Newstalk 810 Radio Carlos Batista Foundation Jack’s Mannequin The Victor E. and Caroline E. Schutte The Harry T. Mangurian, Jr. Beckman Motorsports – Dear Jack Foundation Foundation – Trust E Foundation, Inc.* Big Steaks Management, LLC Virginia Sheldon Jerome Foundation Michael Sheehy Millennium: The Takeda Oncology BMC SELECT Company Pamela B. Katten Memorial Siemens Leukemia Research Foundation Booz Allen Hamilton Novartis Pharmaceuticals, Inc. Sigma Alpha Epsilon Fraternity, Sydney and Isobel Kemper* California Community Foundation University of Georgia Joseph C. Sanfilippo Memorial Fund* Steven and Michele Kirsch Fund, Carlson Family Foundation* Silicon Valley Community Foundation Paul E. Singer Family Foundation* an advised fund of the Silicon Valley Carter’s Babies and Kids Carol Stillwell* United Food & Commercial Workers Community Foundation* Union (UFCW) Cisco Systems, Inc. Team Timko Neil Kishter* United Food & Commercial Workers Clif Bar Family Foundation Paul Touw Laborers’ Charitable Foundation International Union (Canada) Community Health Charities Toyota Rush Limbaugh of Florida TRIB Total Media Timothy and Christine Lindenfelser* Community Health Charities $500,000 – $999,999 Truist The Robert H. Lyon Leukemia of Kansas & Missouri The Beer Store Foundation United Way of the National Cora and John H. Davis Foundation Capital Area Cephalon Oncology Clyde Smith McGregor – In memory Deloitte Valero Energy Foundation F. M. Kirby Foundation* of Joan Kowing McGregor Dominick’s The Valley Foundation Susan Lang Foundation* Michael C. Fina Eli Lilly and Company Washington Area The Newman Family* Nike Dr. Ralph & Marian Falk Mercedes-Benz Dealers The Orokawa Foundation Nissan Medical Research Trust Wilson Farms, Inc. Joseph S. and Diane H. Steinberg Novartis Pharma Canada Inc. France-Merrick Foundation, Inc. Anonymous (1) Charitable Trust* The Olive Garden Italian Restaurant Gap, Inc. Phoenix Partners Group GE Bright Lights PowerBar $10,000 – $49,999 $100,000 – $499,999 Genzyme Corporation 7-Eleven Amgen, Inc. Quest Diagnostics, Inc. The Ryan Gibson Foundation 97.1 WASH-FM Austaco, Inc. Richard and Nancy C. Rogers Google AAPI of Central Ohio Robert and JoAnna Behl* Runner’s World W. W. Grainger, Inc. ACS, A Xerox Company Peter Bing* Salt River Pima-Maicopa Indian Walter and Beth Grant* Community/Casino Arizona Ann Adams The Stephen Birnbaum Foundation* Hargrove Schwinn Howell and Madeline Adams, Jr., Bristol-Myers Squibb Company Leon W. (Pete) Harman – In memory of Madeline Adams Silicon Valley Bank Peter Burg Memorial Research Fund HCA Adobe Smigel, Anderson & Sacks Carter’s, Inc. Betty Ruth and Milton Hollander Aegis Stater Bros. Markets Guy Chiarello Teresa J. Huber Aetna Foundation TUAC Québec Citi Industrial Alliance AIG Highstar Vistar Corporation Citrix Systems Innovative Event Production (IEP) AK Steel Foundation Wawa Community Health Charities Johnson & Johnson Alaska Airlines of New England The Harry & Jeanette Weinberg Foundation, Inc. Karyn Research Fund* Alberto-Culver Company Guy Del Grande Wells Fargo Kiere Media, LLC Dallas Saint Valentine’s Luncheon and Fashion Show Anonymous (2) Lighthouse Investment Partners, LLC *Denotes multi-year commitment
The Leukemia & Lymphoma Society 21 Donors Continued The Community Foundation for the National Capital Region
Eileen Burg Community Health Charities of Alabama Burnham Family Foundation Community Health Charities Burson-Marsteller of Arizona Beckloff Associates Butler Family Foundation Community Health Charities Alcalde & Fay Brian and Lisa Bee – Spin 4 the Cure of Colorado CA, Inc. Alchemy Brewers Association The Beerman Foundation Community Health Charities John Cademartori of Georgia Allegis Group Stefan Belanic Legacy Fund Anthony and Deborah Campbell Community Health Charities Alliance Data The Bell Family Foundation Campbell & Company of Illinois Alliance Holdings, Inc. Bell Microproducts Samuel C. Cantor Charitable Trust Community Health Charities The Altschul Foundation The Belvedere Cove Foundation of Iowa CapitalSource – Reichman Memorial BERT SMITH & Co. Community Health Charities Capitol Broadcasting Company Alyssa’s Crew of Kentucky Best Brands Corporation Capitol File Magazine American Construction Co., Inc. Community Health Charities BET Networks CareFirst BlueCross BlueShield of Maryland American Electric Power The BGR Foundation, Inc. CARFAX, Inc. Community Health Charities America’s Charities BGR Group of Michigan James Carmack America’s Health Insurance Plans Bierman, Geesing & Ward, LLC Community Health Charities (AHIP) Don and Linda Carter of Minnesota Clyde and Rosie Billman Helen Anbinder Carter BloodCare Community Health Charities Bingham McCutchen, LLP Stephen and Madeline Anbinder Thomas and Agnes Carvel Foundation of New York Alexandra Mayes Birnbaum Shaya Ansari CBC Radio Canada Community Health Charities Bill and Nicki Black of Texas Anthem Insurance Companies, Inc. Celebree Learning Centers Phillip Black Community Health Charities Apache Corporation The Center For Executive of the National Capital Area The Blackstone Charitable Foundation Development, Inc. The Apatow Family Foundation, Inc. Community Health Charities Blue Moon Fund Central Blood Bank Argonne National Laboratory of Virginia Blue Shield of California Centric Bank Arizona Public Service Computer Aid, Inc. The Blumenfeld Family CFACQ ATR International The Bob Cooper CLL Research Fund BNY Mellon CGI Group, Inc. AutoTrader.com Alverin M. Cornell Foundation The Boardwalk CGI Federal Awesco Costco Wholesale Bruce Bocina CH2M Hill Charles Baker The Meredith A. Cowden Foundation Boeing Employees Community Fund Harvey Chaplin Baker Botts, LLP Rick and Debby Cox Bognar & Company, Inc. The Rhoda and David Chase Tim Banazek Richard Cox Family Foundation, Inc.* Herman and Emmie Bolden Banc of America Securities, LLC Creative Escape/Bazzill Basics Paper Chemel Kornic & Company, LLC Boston Millennia Partners Bank of America Credit Suisse Chiaramonte Construction Company BP Bank of Tokyo – Mitsubishi UFJ, Ltd. Credit Suisse Americas Foundation The Children’s Mercy Hospital BP Fabric of America Fund Donna Baran The Cromar Foundation Chill Media Inc. Michael Bradley Barclays Bank Delaware Crowe Horwath, LLP Cintas Ronald M. Bradley Foundation Barefoot Wine & Bubbly Cruise Industry Charitable Foundation Citigroup Corporate Helen Brach Foundation Bartimus Frickleton Robertson and Investment Banking DaHunt For The Cure, LLC & Gorny Brass-Craft The Classic Catering People Dana-Farber Cancer Institute Carol Bartz Brayton Purcell Cleary Gottlieb Steen & Hamilton, LLP Danford Foundation BASF, The Chemical Company The Breeden-Adams Foundation Bruce and Isobel Cleland Randy & Deborah Daniel Family Stephen Bauer Brewers of Indiana Guild, Inc. Charitable Foundation Cleveland Indians Baseball Company Bay Family Foundation The Eli and Edythe Broad Foundation DARCARS CN BBVA Compass Bank Peter and Janice Brock The Darvish Family The Cobalt Foundation, Inc. Hildegarde D. Becher Foundation, Inc. Broward Health Donald and Leona Davis Columns Resource Group The Bill Bernbach Foundation The Brown Family Foundation, Inc. Davis-Moore Auto Group BD Biosciences Brown & Gould, LLP Combined Health Agencies DC Rental BDO Seidman, LLP The Bryce Foundation Comcast Del Monte Foods The Beck Group BT Commerce Bank Dell Inc. Greg and Michelle Becker Building Hope Community Blood Center Delta Energy, LLC
22 Delta Health Systems Grace J. Fippinger Foundation John DeRosa Fishing Bay Yacht Club, Inc. Stella B. Gross Charitable Trust Deutsche Bank Fitzgerald Family Foundation Guaranteed Rate DeWaay Capital Management Jodie Flint Jared Coones Pumpkin Run/Walk H&R Block Diagnostic and Interventional Foley & Lardner LLP JDP Mechanical, Inc. Hamill Family Trust Spinal Care The Beverly M. Folger Foundation JFK Medical Center Foundation, Inc. The Handlery Foundation Diplomat Country Club and Spa The For Julie Foundation, Inc. The John Theurer Cancer Center Harkins Builders Dive N’ Surf at Hackensack University FoxKiser Haugh Family Charitable Foundation Medical Center DLA Piper, LLP (US) John & Mary Franklin Foundation HB Group Insurance Management Ltd. Violet M. Johnson Family Foundation Dominion Foundation David Frantze Headstrong Foundation Ralph and Sally Jones Dominion Homes Fraser High School HealthOne Just Give Dominion Resources, Inc. Laurel Friedman Jim Healy Gerald Kafka and Rita Cavanagh Christopher Dorr Memorial Friends of Heroes Heartland Health Kaiser Permanente Duff & Phelps Frieze Harley-Davidson Ride The Helis Foundation Daniel and Susan Kane Duquesne Light Corporation Paul N. Frimmer, Esq. The Hendin Family The Karches Foundation E. P. Vaughan Beneficiaries, U.S. Bank FTI Consulting, Inc. Private Client Group Michelle Henkel Gary and Rochelle Katz Catherine Fugazy Eckert Seamans Cherin & Mellott, LLC Timothy Henkel Steven Kaufmann Fulbright & Jaworski, LLP Ed Voyles Automotive Group Herbert Homes, Inc. The Kaufman Family Foundation Furniture Fair EFESTE Winery Heritage Bag Company The Keane Group Foundation Mrs. Dorothy C. Fuqua James L. Eichberg Foundation, Inc. Highmark BlueCross BlueShield Christopher Kearns J.B. Fuqua Foundation Steven Eisenstadt Lester and Ellen Hightower John Kellenyi G&T Sports Medicine Elite Fitness Systems Phil and Wendy Hildebrand David and Susie Kelley Courtney Knight Gaines Elliott Bay Marina HITT Contracting, Inc. Douglas R. Kenny and Family Foundation, Inc. Ellsworth Corporation Freddie Hoffman Kent Family Charitable Foundation Galen College of Nursing Embassy Suites Hotel Monterey Bay Hogan & Hartson, LLP Kent’s 5K Run Garden City Turkey Trot Race Emergent BioSolutions, Inc. Committee Holland & Knight John and Carol Kerins Emerson Motor Technologies Garden Court Hotel Holt Lunsford Commercial Kettering Health Network Real Estate, Inc. Endo Pharmaceuticals Bill & Melinda Gates Foundation Key Banc Capital Markets Michelle Lunn Hope Foundation Energy Enterprise Solutions, LLC GE Capital Kia Motors of America The Horizon Foundation The Enrichment Foundation GE Foundation Ron and Rosie Kilpatrick for New Jersey Enterprise Holdings Foundation GEICO King & Spalding, LLP The Howard Family Foundation Enterprise Rent-A-Car GEICO Philanthropic Foundation David Kirlin Howrey, LLP Epsilon Data Management, LLC General Dynamics C4 Systems, Inc. The Klein Family Foundation, Inc. Hoxworth Blood Center Equipe de I’INO General Dynamics Information Kluth Family Foundation HSBC Bank USA, N.A. Technology Equipe Josie Kohl’s Human Genome Sciences, Inc. Georgia Power Foundation, Inc. Ernst & Young LLP The Kolache Factory Humana, Inc. – Great Lakes Region R. M. Gerstacker Foundation The Escher Foundation The Arthur Kontos Foundation Bruce & Priscilla Hutchins Family GetWellNetwork, Inc. John Esposito Legacy Endowment KPMG LLP Gila River Gaming Enterprises Euro RSCG Life Hy-Vee, Inc. Charles and Lynda Kraemer Peter and Ann Gilbert ExecutiveBiz.com IBM Employee Services Center Mark and Christine Kraemer Goat Brothers Exotech, Inc. ICAP Services North America, LLC Kraft Foods, Inc. Sheila Gold Foundation F.A.L.L. Classic In Memory of Dixie Shadow The Jeannette and H. Peter Kriendler Goldman, Sachs & Co. Charitable Trust Fairmont Hotels & Resorts In Memory of Maxwell Mason Jewell Gerry Golub Kritchman Family Foundation, Inc. Farmer Mac Independent Health John Goodish The Kroger Co. FARO Technologies, Inc. Infinity Technology LLC Frederick and Rosemary Goodwin Douglas Kroll Research Foundation Suzanne Fedder Insulators Health Hazard Fund Great American Insurance Group The Krutz Foundation FedEx Office Investment Technology Group, Inc. Great Harvest Franchising, Inc. KST Data Inc. Anita Fialkow Investors Group Charitable Theodore and Debra Green Giving Program Mike and Kathy Ladra Fidelity Charitable Gift Fund Greenberg Traurig, LLP J.T. Tai & Co. Foundation The Cortland Finnegan ARK 31 Foundation Dawson Grimsley The Jim Jacobs Charitable Foundation *Denotes multi-year commitment
The Leukemia & Lymphoma Society 23 Continued Ping Y. Tai Foundation, Inc. Donors The Nassi Group, LLC Pittsburgh Pirates National Cooperative Services Corporation Plaid Pantries, Inc. National Rural Utilities Cooperative Planned Systems International Finance Corporation PNC Bank NBC5 McFee Foundation PNC Bank Foundation Thomas Neill Casey McGlynn Polo Ralph Lauren Foundation Nestle Purina Laffey McHugh Foundation Sean and Erin McGould Antonio B. and Rita M. Pomerleau NetApp Foundation, Inc. Linda LaGorga McKesson Corporation Foundation, Inc. The Netter Foundation Dave and Teri Pool Diane S. Lake Family McKinsey & Company, Inc. New York Community Bancorp, Inc. Poster Family Foundation Marie Lamfrom Charitable Foundation McKinstry New York State Union of Teachers Powell Industries Lanier Parking Solutions The Gerald and Paula McNichols Kenneth and Bonni Newton Prairie Farms Dairy Bombardier Learjet Employees Family Foundation Care Fund Nicholas Family Foundation Prairie Meadows Meadow Gardens Ladies Invitational Lisa Leder Guy and Linda Nohra The Pray Family Foundation Golf Tournament John Lefebvre Northrop Grumman PRDC MedAssets The Len-Ari Foundation, Inc. Northside Hospital John and Monika Preston MedImmune Les Déterminés Northwestern Mutual Foundation Price Modern, LLC The Memorial Foundation Les Invincibles Norton Cancer Institute Protiviti, Inc. Memorial Healthcare System Steven Lieblich NRG Energy, Inc. Providence Alaska Medical Center Menkes Development Inc. LifeSource Morgan O’Brien Puyallup Tribe of Indians Merck & Co., Inc. Lightner Sams Foundation, Inc. Occidental Petroleum Corporation Rabobank Meredith Corporation Foundation Carl Lindner The Ohio State University Ralf Helmig Trust of 2008 Metro Waste Comprehensive Cancer Center Marlene and Andrew Lippmann Rally Foundation for Childhood MicroLink, LLC – James Cancer Hospital Cancer Research List Innovative Solutions and Solove Research Institute Microsoft Corporation/Federal Stuart and Barbara Ray Dorajean Littrell Systems Division Old Westbury Golf & Country Club Raytheon Company Peter and Tina Locke Microsoft Matching Gifts Program Oncology Center of Central Baltimore RBC Capital Markets Lockheed Martin Corporation The Mifsud Family The W. O’Neil Foundation RBC Foundation Lockton, Inc. Mike Hunter’s Team Onyx Pharmaceuticals, Inc. Redfall Financial Lowndes, Drosdick, Doster, Pam Miller Oracle Kantor & Reed, P.A. Regence James Milligan Osprey Foundation Lumina Foundation The Regence Group Patrick and Nancy Minan OU Medicine – In honor of Steven Hooker Lundbeck Inc. Edward Miner Betty Owens Francis X. and Susan Reinhardt Lukas Lundin Suzy Minkoff Oxford Development Roberta Reitzes M&T Charitable Foundation MIQ Logistics Dave and Patti Pace Remillard Family Foundation M&I Bank Mission Foods Corporation Palmetto Ford James Resnick MacCutcheon Family Foundation Mizuho Corporate Bank, Ltd. The Pampered Chef Reznick Group Mack Madness MLB Advanced Media, LP Parents Against Leukemia Riemer & Braunstein, LLP Mackenzie Partners, Inc. Lori Mody Park Place Motorcars Dallas Risen & Inch Macquarie Group Foundation Monster Mechanical, Inc. Peoples Health Rite Aid Corporation The Mammel Foundation Moody Foundation Peoples Natural Gas RMD Corporation The Samuel P. Mandell Foundation Morgan Borszcz Consulting PEPCO Al Roadburg Foundation Peter and Gina Manos Morgan Stanley PepsiCo, Inc. Robert Michael Communications, Inc. Roxanne Marino MorganFranklin Corporation The Steven M. Perez Foundation Edith Roberts Marriott International, Inc. Jonathan Morris James Pettus Eddie Robinson The Master’s Hands Foundation Antoine Munfa PGT Trucking, Inc. Ruth Robinson Matthew’s Team Murray & Guari Phi Gamma Delta Fraternity Rocky Mountain Blood and Marrow Mary E. McCaul Joseph Naggar Phillips-Van Heusen Transplant Program Cole and Vickie McClendon The Najim Family Foundation Phillips-Van Heusen Foundation The Drew Rodrigue Foundation – Rope for Hope Names Family Foundation Piedmont Healthcare Peter and Lynn Rogers McCownGordon Construction, LLC Larry and Leslie Nance Chad Pike Rogers Family Foundation The June & Cecil McDole Charitable Fund Nartel Family Foundation Pillsbury Winthrop Shaw Pittman, LLP The Rogers Foundation
24 The Theodore Rosenberg Charitable Foundation Blake Shelton Jerry and Lois Rosenblum Targeting Lymphoma Shoot Mike and Claire Shevlin Matt Rosenthal – Links For Leukemia Brian and Diana Taussig Sandra Rosenthal The Shimkin Foundation TBD Foundation, an advised fund of the Silicon Valley Amanda Ross Siebert Brandford Shank & Co., LLC Community Foundation Royal Bank of Canada Simmonds Family Foundation Denny and Diana Walker TDS Metrocom The Royal Bank of Scotland The Sidney, Milton Walton Construction Team Chad & Leoma Simon Foundation Royals Charities Linda Walty Team EMC Douglas A. and Phyllis Smith RR Donnelley Washington Area Toyota Dealers Team Luca Elaine Smith Association, Inc. RREEF Technology Concepts & Design, Inc. Smith Productions Washington Business Journal Paul and Joan Rubschlager Foundation Texas Instruments Marketing Group Kevin Sneader Washington Gas The Ruby Restaurant Group – In Memory of Raj Gupta Soccer Against Leukemia & Lymphoma The Washington Post & Cars.com Rural Telephone Finance Cooperative Texas Roadhouse Gloria Somerville Wagner Washingtonian Christopher Russell Rick and Susan Theder Sony, Inc. The Watkins Family Jeff and Pat Sachs Michael and Jacqueline Thomas Southeast Nebraska Hematology Watkins Meegan, LLC John Salata Gillis and Billie Thomas & Oncology Wawanesa Insurance Company Salesforce.com Foundation Rodney Thompson SouthWest Bank Lisa Weber Sallie Mae, Inc. Thompson Habib Denison (THD) Spangenberg Family Foundation Wechsler/Marsico Associates The San Francisco Foundation Becca Cason Thrash John W. & Effie E. Speas Memorial Trust The Stone and Holt Weeks Foundation SanDisk Edgar A. Thronson Foundation, Inc. Spire Corporation Wendy’s of Michigan Sandra Atlas Bass Foundation Thunderbirds Charities Mark and Carol Spisak West Penn Allegheny Health System Sanofi Aventis Tiber Creek Partners, LLC Sprint Westchester Tri Team Santa Clara Marriott Title Associates SRA International The Frederick and Margaret L. Sarver Charitable Trust Too Hot To Trot St. Joseph’s Candler Weyerhaeuser Foundation David and Kim Savage Towers Watson St. Luke’s Mountain States Wheeler Family Charitable Foundation – Megan’s Wings, Inc. Tumor Institute Trainos Wine & Spirits Charlie and Shelley Whetzel John and Jana Scarpa St. Vincent de Paul Foundation, Inc. Trans-Siberian Orchestra White Castle Stephen Scherr Stanley Korshak Transwestern WiLine Networks Schnucks Markets State of New York James Triantos Brett Williams The Marge & Charles J. Schott Department of Health Triton Hardanding Service Foundation Mark and Sharon Williams The Doug Steele Family – Doug Steele Truland Service Corporation The Victor E. and Caroline E. Schutte Golf Fore Life Tournament James and Judith Wilson Foundation – 1959 Trump Entertainment Stephanie Walker Fund Winston & Strawn, LLP Schwab Charitable Fund Igor Tsyganskiy John Stewart WIVB-TV, Channel 4 Edith M. Schweckendieck Trusts Tube City IMS Ken and Ann Stinson Richard and Kaye Woltman Scotia Capital Turner Interiors Stinson, Morrison, Hecker, LLP Woodbine Entertainment Group Scott Health & Safety Jack A. Turpin Structure Tone, Inc. The Carl M. Woolford Foundation, Inc. Searcy Denney Scarola Barnhart U.S. Bank Sun Dun, Inc. of Washington WTOP Radio & Shipley, PA U.S. Bank Private Client Frank Sunberg WUSA9 Sedano’s Supermarkets & Trust Services Harry Sunenshine Wyeth Pharmaceuticals Melissa Segal* UBS Securities, LLC SunTrust Bank Daniel Wyner Isador S. Segall Trust Unanet Technologies SUPERVALU Wyse Technology Serco, Inc. Unisys Corporation SureTec The Yahoo Employee Foundation Angelo and Anne Settembrini United Space Alliance, LLC Susan Mott Webb Charitable Trust Mina Yanney Sewell Cadillac United States Steel Corporation Sweet Ovations Eric and Tamara Yollick Shadowitz Family and Friends UnitedHealthcare Michael Sweig Young Hearts Kevin Shannahan University of Pittsburgh Swinging for a Cure Medical Center John and Adelaide Zabriskie The Earl and Brenda Shapiro Foundation Syringa Networks Valley Jewlery & Loan Ziolkowski Patent Solutions Group Shavlik Technologies, LLC Sysmex America, Inc. Joseph and Drenda Vijuk Joseph Zvesper The William J. Shaw Family Foundation T Wall Properties The Vons Foundation Anonymous (10) The Shawver Family Sheri Tackett Wachovia Wells Fargo Foundation Sheehy Lexus of Annapolis Target Corporation Waddell & Reed Kansas City Marathon *Denotes multi-year commitment
The Leukemia & Lymphoma Society 25 Donors Continued Legacy Top Campaign Fundraisers Circle Individuals who have raised more than $50,000 or company teams that have raised more than $100,000 to support LLS’s mission.
Rose Astorina Legacy Circle honors those who name LLS in their wills, or as beneficiaries of Austaco, Inc. a trust, retirement account or insurance policy or enter into a charitable gift Ryan LaFontaine annuity. We list our newest members below along with those whose bequests Carolyn Balling Michael Lapicki of $10,000 or more were received this year. Barclays Capital Daniel S. Lasik Jack Beckman Dr. Alan Lichtin Irene Ambrosius* Sadie Melton* Janice Bender* Steven Lilly Lorraine Azrak* Ethel Meyer* The Blackstone Group Robin Lineberger Louise Barrows* Stephen Milazzo The Blumenfeld Family The Lymphomaniacs Melvin Baum* Robert Mitchell* Burlington Coat Factory J. David Mahoney Roy and Anna Bergren* June Moran* Annie Caltabiano David Mammina Andrew and Edith Berto* Jane Moshman Carter’s Babies and Kids James Marchewka Alyce Biglia* Dorothy Mueller* Hope Cherry Edye McCarthy Samuel and Elenor Bjorkman* Martin Mullen* Citi Mary McLaughlin Edward and Christina Blanchard Jean Murray* Citrix Systems & The BELIEVE Campaign Camille Blok Maria Nechi* Coach, Inc. Justin McMaster Michael Boyne* Nancy Newman* Andy Collins Lance Meyerowich Elizabeth Brady Mary Ann Nielsen* Jonna Kirke Crandell Michael C. Fina Marcia Brown* Ralph and Carol Odgers* Credit Suisse Bob Mills* Hester Joyce Burtenshaw* William H. Owen* Dan Darcy & Band Against Marc Moore Roger Busch* Andrew and Mary Passafaro* Blood Cancer Sarah Moore Coy and Lucille Byerly* Susan Pax* Jim Davis Steve Movius Jean Carlisle* Ila Plantz* Deloitte Pat Mozersky John Carlson* Jerry Price Delta Energy, LLC Novartis Jenna Cavin Dennis Primeaux* Tam Driscoll Ed Offterdinger Barry Clayton* Rade Ratkovic* Lisa Dunn Lisa Pagano & Stand Up Take Notice Lauren Cohen* Margaret Reed* Frances Duprey Steve Paschos Dorothy Cox* David Reynolds* Elbit Systems of America, LLC Quest Diagnostics, Inc. William and Lorraine Dalton* Randall Richards Ashley Erickson Steve Richbourg William Robert Davidson* Dorothy Rittler* Evelyn Erives & On Air Care The Riders of the Storm Martha DeAnda Stella Sabatelle Ernst & Young LLP Mary Kathryn Rodrigue William DeLoach Richard Scharff* Joey Fago Katie Rost & Team Believe Nelson Doland* Delores Schommer* Darin Ferguson Joe Sadowski Peggy and Margaret Dupaquier* Alice Scott* Cary Fishburne Jared Salvetti Charles Edlin* Scott Shields James Fitzgerald Silicon Valley Bank Christina Evers* Mr. and Mrs. Howard Silver Alexandria Freydberg & PC Yuliya Singo Robert and Carolyn Flood* Myra Smith Commandos Ted St. Pierre Robert Gale* Sally Smith* Sean Geiger & Raising Hope Stater Bros. Markets John Gallo* Robert Sommer* Georgia Chain Gang Peter Strang Linda Gunther* Francis Speiser* Georgia Pest Control Association Fernando Suarez John Russell Harris, Jr. Irene Stevenson* Katherine G. Giuffre Jaclyn Toll Judith Helfant* Bruce and Anne Swartz* The Greene Team Vin Tormo Gregg Hinckley* Florence Thornhill* Mary Hellerstedt Valero Energy Corporation Virginia Hoffman* Elenora Tolliver Michelle Henkel Vistar Donald Howarth* Bud and Vickie Urban Josh Horowitz Brad F. Wagner Selma Karr Ira Weiner Kiven, Kotler, Lieberman, Fox, Joffe, Elizabeth Wahler Catherine Jean Wickenden Mooney* Goldschmidt & Kepes Team Maxine Kilner* Dr. Stanley Walker James Woods Jack’s Mannequin Virginia Kintz* – Dear Jack Foundation Martha Whitecotton Lillian Kraus* Elsie Wunsch* Travis Janovich Beth R. Wiesner Maurice Krisel Dolores Zaino* Daniel S. Johnson Yahoo Lawrence Lane* Joleen Zeller* Joseph B. Kelley Dr. Zimmerman Barbara Louis* Anonymous (3) William Kenny Yvonne Lucassen* Thomas Klein * National Man & Woman of the Year Martha Elizabeth Maitland* * Deceased
26 Independent Auditors’ Report
The Board of Directors The Leukemia & Lymphoma Society, Inc.:
We have audited the accompanying consolidated statement of financial position of The Leukemia & Lymphoma Society, Inc. (LLS) as of June 30, 2010, and the related consolidated statements of activities, functional expenses, and cash flows for the year then ended. These consolidated financial statements are the responsibility of LLS’s management. Our responsibility is to express an opinion on these consolidated financial statements based on our audit. The prior year summarized comparative information has been derived from LLS’s 2009 consolidated financial statements and, in our report dated September 15, 2009, we expressed an unqualified opinion on those statements.
We conducted our audit in accordance with auditing standards generally accepted in the United States of America. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. An audit includes consideration of internal control over financial reporting as a basis for designing audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of LLS’s internal control over financial reporting. Accordingly, we express no such opinion. An audit also includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements, assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation. We believe that our audit provides a reasonable basis for our opinion.
In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the financial position of The Leukemia & Lymphoma Society, Inc. as of June 30, 2010, and the changes in its net assets and its cash flows for the year then ended in conformity with U.S. generally accepted accounting principles.
September 15, 2010 New York, New York
The Leukemia & Lymphoma Society 27 Consolidated Statement of
The Leukemia & Lymphoma Society, Inc. > June 30, 2010 Financial Position (With comparative amounts at June 30, 2009) (In thousands)
2010 2009 Assets
Cash and cash equivalents $ 21,196 $ 28,196 Prepaid expenses and other assets 4,577 4,314 Accounts receivable 130 75 Legacies and contributions receivable, net (note 2) 18,417 22,752 Investments (note 3) 177,489 161,623 Fixed assets, less accumulated depreciation and amortization of $7,965 and $12,544 5,132 4,616
Total assets $ 226,941 $ 221,576
Liabilities and Net Assets
Liabilities: Accounts payable and accrued expenses $ 16,448 $ 14,682 Deferred revenue 16,940 15,479 Grants payable (notes 4 and 5) 80,580 85,768 Total liabilities 113,968 115,929
Net assets (note 9): Unrestricted 88,617 78,551 Temporarily restricted 20,668 23,596 Permanently restricted 3,688 3,500 Total net assets 112,973 105,647
Total liabilities and net assets $ 226,941 $ 221,576
See accompanying notes to consolidated financial statements.
28 Consolidated Statement of
The Leukemia & Lymphoma Society, Inc. > Year ended June 30, 2010 Activities (With summarized totals for the year ended June 30, 2009) (In thousands)
Temporarily Permanently Total Unrestricted Restricted Restricted 2010 2009 Revenue
Campaign contributions $ 247,939 $ 31,885 $ 84 $ 279,908 $ 291,521 Less direct donor benefit costs (36,635) – – (36,635) (39,077) Net campaign contributions 211,304 31,885 84 243,273 252,444 Legacies 4,045 3,009 – 7,054 26,459 Donated services (note 1) 6,819 – – 6,819 6,829 Net interest and dividend income (note 3) 4,351 53 26 4,430 6,467 Net increase (decrease) in fair value of investments 11,238 19 78 11,335 (7,315) Grant refunds 1,897 – – 1,897 2,768 Net assets released from restrictions 37,894 (37,894) – – –
Total revenue 277,548 (2,928) 188 274,808 287,652
Expenses (note 10)
Program Services: Research 70,910 – – 70,910 69,786 Patient and community service 83,406 – – 83,406 93,448 Public health education 41,597 – – 41,597 41,331 Professional education 8,073 – – 8,073 8,497
Total program services 203,986 – – 203,986 213,062 Supporting Services: Management and general 22,462 – – 22,462 23,259 Fund raising 41,255 – – 41,255 43,132
Total supporting services 63,717 – – 63,717 66,391
Total expenses 267,703 – – 267,703 279,453 Change in net assets before foreign currency translation adjustment 9,845 (2,928) 188 7,105 8,199
Foreign currency translation adjustment 221 – – 221 (648) Change in net assets 10,066 (2,928) 188 7,326 7,551
Net Assets
Beginning of year 78,551 23,596 3,500 105,647 98,096 End of year $ 88,617 $ 20,668 $ 3,688 $ 112,973 $ 105,647
See accompanying notes to consolidated financial statements.
The Leukemia & Lymphoma Society 29 Consolidated Statement of
The Leukemia & Lymphoma Society, Inc. > Year ended June 30, 2010 Functional Expenses (With comparative totals for the year ended June 30, 2009) (In thousands)
Program Services Supporting Services Patient and Public Management Direct donor community health Professional and Fund Total benefit costs Research service education education Total general raising Total 2010 2009 2010 2009 Awards and grants $ 58,714 $ – $ – $ – $ 58,714 $ – $ – $ – $ 58,714 $ 63,542 $ – $ – Therapy acceleration program (note 6) 8,227 – – – 8,227 – – – 8,227 2,294 – – Financial aid to patients – 6,059 – – 6,059 – – – 6,059 7,437 – – Co-pay assistance (note 5) – 14,003 – – 14,003 – – – 14,003 19,211 – – Donated services 1,034 5,785 – – 6,819 – – – 6,819 6,829 – – Salaries 1,339 27,758 15,886 4,191 49,174 7,463 9,013 16,476 65,650 71,606 – – Employee benefits and taxes(note 7) 223 7,612 4,929 1,258 14,022 2,142 3,261 5,403 19,425 19,792 – – Occupancy (note 8) 40 3,378 2,363 631 6,412 1,043 1,389 2,432 8,844 9,172 – – Insurance 10 212 159 28 409 57 113 170 579 632 – – Telephone 36 1,844 1,036 167 3,083 304 1,031 1,335 4,418 5,211 – – Travel 48 754 549 139 1,490 293 318 611 2,101 2,305 11,633 13,054 Printing and supplies 183 2,707 5,901 378 9,169 3,762 8,746 12,508 21,677 21,812 5,813 5,781 Equipment rentals and maintenance 15 705 486 124 1,330 212 316 528 1,858 2,221 – – Postage and shipping 18 993 3,676 140 4,827 1,942 6,253 8,195 13,022 13,535 – – Meetings 423 2,396 753 204 3,776 359 412 771 4,547 4,273 8,965 9,127 Professional fees 567 7,430 4,731 509 13,237 4,212 9,646 13,858 27,095 25,101 3,496 3,776 Miscellaneous 6 1,100 672 204 1,982 493 410 903 2,885 2,763 6,728 7,339 Depreciation and amortization 27 670 456 100 1,253 180 347 527 1,780 1,717 – – Total expenses $ 70,910 $ 83,406 $ 41,597 $ 8,073 $ 203,986 $ 22,462 $ 41,255 $ 63,717 $ 267,703 $279,453 $ 36,635 $ 39,077
See accompanying notes to consolidated financial statements.
Research 26.5% Expenses Patient and Community Service 31.2% Public Health Education 15.5% Professional Education 3.0% Total Program Services 76.2%
Management and General 8.4% Fundraising 15.4% Total Supporting Services 23.8%
Total Expenses 100.0%
30 Consolidated Statement of
The Leukemia & Lymphoma Society, Inc. > Year ended June 30, 2010 Cash Flows (With comparative amounts for the year ended June 30, 2009) (In thousands)
2010 2009 Cash flows from operating activities:
Change in net assets $ 7,326 $ 7,551
Adjustments to reconcile change in net assets to net cash used in operating activities:
Net (increase) decrease in fair value of investments (11,335) 7,315 Permanently restricted revenue collected (84) (119) Depreciation and amortization 1,780 1,717 Increase in allowance for uncollectible accounts 415 413
Changes in operating assets and liabilities:
Prepaid expenses and other assets (263) 493 Accounts receivable (55) 1,285 Legacies and contributions receivable 3,920 (15,998) Accounts payable and accrued expenses 1,766 (6,018) Deferred revenue 1,461 (1,695) Grants payable (5,188) 4,098
Net cash used in operating activities (257) (958)
Cash flows from investing activities:
Purchases of fixed assets (2,296) (1,185) Purchases of investments (119,968) (186,225) Sales of investments 115,437 180,265
Net cash used in investing activities (6,827) (7,145)
Cash flows from financing activities:
Permanently restricted contributions collected 84 119
Net cash provided by financing activities 84 119
Net decrease in cash and cash equivalents (7,000) (7,984) Cash and cash equivalents at beginning of year 28,196 36,180
Cash and cash equivalents at end of year $ 21,196 $ 28,196
See accompanying notes to consolidated financial statements.
The Leukemia & Lymphoma Society 31 Notes to Consolidated Financial Statements
The Leukemia & Lymphoma Society, Inc. > June 30, 2010 (with comparative amounts as of and for the year ended June 30, 2009)
1. Organization and Significant Accounting Policies Organization The Leukemia & Lymphoma Society, Inc. (LLS) is an international not-for-profit health agency dedicated to seeking the cause and cure of leukemia, lymphoma, Hodgkin’s disease, and myeloma and improving the quality of life of patients Temporarily restricted net assets: Consist of funds that are restricted and their families. LLS’s principal activities include: awarding research grants; by donors for a specific time period or purpose. facilitating psychosocial support groups; providing financial aid to patients; Permanently restricted net assets: Consist of funds that contain donor-imposed answering phone requests for blood cancer information made to LLS’s restrictions requiring that the principal be invested in perpetuity and that Information Resource Center; and disseminating educational information only the income be used. Income earned on these funds may be unrestricted about blood cancers in the form of publications, internet sites, conference or temporarily restricted, depending upon the donor-imposed restrictions. calls, and symposia sponsorship for both the medical community and the Foreign Currency Translation general public. LLSC uses the Canadian dollar as its functional currency. Accordingly, the currency Tax-Exempt Status impact of the translation of the financial statements of LLSC to U.S. dollars is LLS qualifies as a charitable organization as defined by Internal Revenue included as a translation adjustment in the consolidated statement of activities. Code Section 501(c)(3) and, accordingly, is exempt from federal income Fair Value Measurements taxes under Internal Revenue Code Section 501(a). Additionally, since LLS Fair value is defined as the exchange price that would be received for an asset is publicly-supported, contributions to LLS qualify for the maximum charitable or paid to transfer a liability (an exit price) in the principal or most advantageous contribution deduction under the Internal Revenue Code. market for the asset or liability in an orderly transaction between market participants The Leukemia & Lymphoma Society of Canada, Inc. (LLSC) is registered as at the measurement date. The three levels of the fair value hierarchy are as follows: a charitable organization under the Income Tax Act (Canada) and, is therefore, Level 1 inputs are quoted prices (unadjusted) in active markets for identical not subject to income taxes if certain disbursement requirements are met. assets or liabilities that a reporting entity has the ability to access at the Principles of Consolidation measurement date. The accompanying consolidated financial statements include the accounts Level 2 inputs are inputs other than quoted prices included within Level 1 of LLS, which encompasses the Home Office of LLS and its fifty-five chapters that are observable for the asset or liability, either directly or indirectly. in the United States, LLSC, and LLS’s not-for-profit affiliates, The Leukemia & Lymphoma Society Research Programs, Inc. and The Leukemia & Lymphoma Level 3 inputs are unobservable inputs for the asset or liability. Society Research Foundation. All significant intercompany and intra-LLS accounts LLS follows the provisions of Accounting Standards Codification (ASC) 820, and transactions have been eliminated in consolidation. Investments in Certain Entities That Calculate Net Asset Value per Share (or Its Equivalent) Estimates (ASC 820), for certain alternative investments that do not have readily determinable The preparation of the consolidated financial statements in conformity fair values, including hedge funds, limited partnerships, and other funds. This guidance with generally accepted accounting principles requires LLS’s management allows, as a practical expedient, for the estimation of the fair value to make estimates and assumptions that affect the amounts reported in the of investments in investment companies for which the investment does not have consolidated financial statements and accompanying notes. The significant a readily determinable fair value, using net asset value per share or its equivalent, estimates made in the preparation of these consolidated financial statements as reported by the investment managers. include the fair value of alternative investments, the allowance for uncollectible Most investments classified in Levels 2 and 3 consist of shares or units in investment accounts, and the allocation of expenses. Actual results could differ from funds as opposed to direct interests in the funds’ underlying holdings, which may be those estimates. marketable. Because the net asset value reported by each fund is used as a practical Risks and Uncertainties expedient to estimate fair value of LLS’s interest therein, its classification in Level 2 LLS invests in various investment securities. Investment securities are exposed or 3 is based on LLS’s ability to redeem its interest at or near June 30. If the to various risks such as interest rate, market, and credit risks. Due to the level interest can be redeemed in the near term, the investment is classified as Level 2. of risk associated with certain investment securities, it is at least reasonably The classification of investments in the fair value hierarchy is not necessarily an possible that changes in the values of investment securities will occur in the near indication of the risks, liquidity, or degree of difficulty in estimating the fair value term and that such changes could materially affect the amounts reported of each investment’s underlying assets and liabilities. in the statement of financial position. Contributions and Deferred Revenue Summarized Financial Information Contributions are recorded as revenue, at their fair value, when received The consolidated financial statements are presented with 2009 summarized or promised unconditionally. Contributions received with donor restrictions or comparative information. With respect to the consolidated statement that limit their use are reported as either temporarily or permanently restricted of activities, such prior year information is not presented by net asset class revenue. When a donor restriction is met through the passage of time or and, in the consolidated statement of functional expenses, 2009 expenses fulfillment of a purpose restriction, temporarily restricted net assets are reclassified by object are presented in total rather than by functional category. Accordingly, to unrestricted net assets and reported in the consolidated statement of activities such information should be read in conjunction with LLS’s 2009 consolidated as net assets released from restrictions. Conditional contributions are recognized financial statements from which the summarized information was derived. as revenue when the conditions have been substantially met. Subsequent Events Deferred revenue includes amounts received for special events that will be held LLS evaluated subsequent events after the statement of financial position date subsequent to the fiscal year-end. of June 30, 2010 through September 15, 2010, which was the date the consolidated Donated Services financial statements were issued, and concluded that no additional disclosures LLS has determined that certain of the donated services it receives meet are required. the criteria for recognition in the consolidated financial statements. Specifically, Net Asset Classifications the donated services of family support group facilitators and research grant To ensure observance of limitations and restrictions placed on the use of resources reviewers in the amount of $6,819,000 in 2010 and $6,829,000 in 2009 have available to LLS, funds that have similar characteristics have been classified been valued and are reported as both revenue and expense. into three net asset categories as follows: Cash Equivalents Unrestricted net assets: Consist of funds that are fully available, at the Cash equivalents consist of short-term investments with an original maturity discretion of LLS’s Board of Directors, for LLS to utilize in any of its programs of three months or less from date of purchase, except for amounts held or supporting services. for long-term purposes reported as investments.
32 Notes to Consolidated Financial Statements Continued
The Leukemia & Lymphoma Society, Inc. > June 30, 2010 (with comparative amounts as of and for the year ended June 30, 2009)
Investments Investments are stated at fair value based upon quoted market prices, except for the fair values of funds of hedge funds and limited partnerships, which are 2009 Level 1 Level 2 Level 3 based on net asset values provided by the fund managers and general partners, respectively, based upon the underlying net assets of the funds consistent with the Money market funds and cash $ 1,514 $ 1,514 $ – $ – concepts of ASC 820. These values are reviewed and evaluated by management. Fixed income: Fixed Assets and Depreciation Long duration fixed income 64,162 64,162 – – Fixed assets, which consist principally of equipment, software, and leasehold Low duration fixed income 49,216 49,216 – – improvements, are recorded at cost, if purchased, or at fair value at date of donation, Other 3,490 3,490 – – if contributed, and are depreciated or amortized using the straight-line method Equities: over the estimated useful lives of the assets or the terms of the leases, if shorter. Large cap equity 9,817 9,817 – – All cap equity 1,932 1,932 – – Recent Accounting Standards International equity 5,772 5,772 – – In 2010, LLS adopted ASC 740, Accounting for Uncertainty in Income Taxes. LLS Small cap equity 6,394 6,394 – – evaluated the impact of adopting the accounting and disclosure requirements Small/mid cap equity 1,023 1,023 – – of ASC 740 for uncertainties in income taxes recognized in the consolidated financial statements, which prescribes a threshold of more-likely-than-not Alternative investments: for recognition and de-recognition of tax positions taken or expected to be Funds of hedge funds 4,148 2,000 – 2,148 taken in a tax return. There was no significant impact to LLS’s consolidated Limited partnership financial statements as a result of the adoption of ASC 740. equity indices 14,155 – – 14,155 $ 161,623 $ 145,320 $ – $ 16,303 2. Legacies and Contributions Receivable
LLS’s legacies and contributions receivable at June 30, 2010 and 2009 Investment expenses of $580,000 and $568,000 have been netted against interest consist of unconditional promises to give and legacies for which the underlying and dividend income for the years ended June 30, 2010 and 2009, respectively. wills have been declared valid by the probate court and no other conditions The unrealized gains and losses were $10,344,000 and $(5,923,000) for the years are required to be met. Amounts are scheduled to be received as follows ended June 30, 2010 and 2009, respectively. (in thousands): LLS invests in certain alternative investments, through “funds of hedge funds” 2010 2009 investments, which invest in multiple strategies through a portfolio of hedge fund Less than one year $ 16,675 $ 21,154 managers to provide diversification and reduce manager risk. These strategies 1 to 5 years 3,157 2,334 create indirect exposure to LLS through short sales of securities, trading in future After 5 years 232 208 and forward contracts, and other derivative products. Derivatives are investment Subtotal 20,064 23,696 contracts used to hedge risk. While these financial instruments may contain varying Less allowance for degrees of risk, LLS’s risk with respect to such transactions is limited to its capital uncollectible accounts (1,164) (749) balance in each investment. Less discount to present The underlying holdings of the limited partnership equity indices are principally value (5%) (483) (195) domestic and international marketable securities. Total $ 18,417 $ 22,752 LLS’s alternative investments contain various redemption restrictions with required written notice ranging from 70 to 90 days. As of June 30, 2010, the following table Approximately, 54% and 60% of LLS’s legacies and contributions receivable summarizes the composition of such investments at fair value by the various are from one estate at June 30, 2010 and 2009, respectively. redemption provisions (in thousands): Redemption Period Amount 3. Investments Monthly $ 13,003 The following table presents LLS’s fair value hierarchy of investments measured Quarterly 17,461 at fair value on an annual basis as of June 30, 2010 and 2009 (in thousands). 1 year lock-up 15,992 2010 Level 1 Level 2 Level 3 Total $ 46,456
Money market funds and cash $ 537 $ 537 $ – $ – Fixed income: As of June 30, 2010 and 2009, LLS has no unfunded commitments on its alternative Long duration fixed income 53,153 53,153 – – investments. Low duration fixed income 41,787 41,787 – – The following table presents a reconciliation for all Level 3 assets measured Other 3,498 – 3,498 – at fair value as of June 30, 2010 and 2009 (in thousands). Equities: Level 3 Assets Large cap equity 14,149 14,149 – – 2010 2009 International equity 5,572 5,572 – – Small cap equity 3,521 3,283 238 – Balance at July 1 $ 16,303 $ 19,334 Real return 8,175 8,175 – – Purchases 15,750 2,000 Small/mid cap equity 641 – 641 – Investment expense (131) (103) Alternative investments: Investment income – 332 Funds of hedge funds 35,004 – 19,462 15,542 Net increase (decrease) Limited partnership in fair value 286 (5,260) equity indices 11,452 – 11,002 450 Transfers to Level 2 (16,216) –
$ 177,489 $ 126,656 $ 34,841 $ 15,992 Balance at June 30 $ 15,992 $ 16,303
The Leukemia & Lymphoma Society 33 Notes to Consolidated Financial Statements Continued
The Leukemia & Lymphoma Society, Inc. > June 30, 2010 (with comparative amounts as of and for the year ended June 30, 2009)
9. Temporarily and Permanently Restricted Net Assets Temporarily restricted net assets and the income earned on permanently restricted net assets are available for the following purposes at June 30, 2010 and 2009 4. Awards and Grants (in thousands): Awards and grants for research are recognized as expense in the year 2010 2009 approved by LLS’s Board of Directors. Multi-year grants, which are generally Temporarily Permanently Temporarily Permanently Restricted Restricted Restricted Restricted two to five years in length, are approved on an annual basis and may be terminated at the discretion of LLS’s Board of Directors. In addition to Time restrictions $ 12,344 $ – $ 16,566 $ – unconditional grants payable of $80,580,000 at June 30, 2010, LLS has grant Research 3,983 3,123 2,241 2,917 commitments of $67,433,000 that are conditioned upon future events Patient service 4,180 516 4,658 420 and, accordingly, are not recorded. Other 161 49 131 163
Total $ 20,668 $ 3,688 $ 23,596 $ 3,500 5. Co-Pay Assistance Program The Co-Pay Assistance program offers assistance to patients in meeting their LLS follows the Uniform Management of Institutional Funds Act (UMIFA). insurance co-pay obligations for prescription medications or private/public health LLS has interpreted UMIFA as requiring the preservation of the original gift insurance premiums. Amounts awarded under the program are expensed in of the donor-restricted endowment fund absent donor stipulations to the contrary. the year approved based on the available funding in the program. Approximately In September 2010, New York State adopted the Uniform Prudent Management $4,374,000 and $7,448,000 were included in the grants payable balances of Institutional Funds Act. In 2011, LLS will be required to adopt the net asset for amounts awarded but unpaid at June 30, 2010 and 2009, respectively. classification requirements of ASC 958-205,Endowments of Not-for-Profit Organizations: Net Asset Classification of Funds Subject to an Enacted Version 6. Therapy Acceleration Program (TAP) of the Uniform Prudent Management of Institutional Funds Act, and Enhanced TAP is LLS’s strategic initiative to speed the development of blood-cancer Disclosures for All Endowment Funds. treatments and supportive diagnostics by creating business alliances with biotech- The following table presents changes in the donor-restricted endowment funds nology and pharmaceutical companies. TAP provides funding for investigational for the year ended June 30, 2010 (in thousands). new drug-enabling studies and clinical-stage projects. TAP contracts are recognized as an expense in the year program milestones are achieved. Multi-year contracts, Temporarily Permanently Unrestricted restricted restricted Total which are generally two to three years in length, are reviewed against milestones on a quarterly basis and may be terminated at the discretion of LLS’s Board Endowment net assets at July 1 $ 1,396 $ 397 $ 3,500 $ 5,293 of Directors. LLS has contract commitments of $22,230,000 at June 30, 2010 Investment (expense) income (74) 65 104 95 that are conditioned upon future events and, accordingly, are not recorded. Net appreciation 473 – – 473 Contributions – – 84 84 7. Pension Plan Net assets released 100 (100) – – LLS has a defined contribution 403(b) pension plan covering all employees Endowment net assets at June 30 $ 1,895 $ 362 $ 3,688 $ 5,945
meeting age and service requirements. Contributions are based on a percentage of each eligible employee’s salary and years of service. Expense under this plan The following table presents changes in the donor-restricted endowment funds aggregated $4,072,000 and $4,105,000 for the years ended June 30, 2010 for the year ended June 30, 2009 (in thousands). and 2009, respectively. Temporarily Permanently Unrestricted restricted restricted Total LLS has a 457(b) deferred compensation plan (the 457 Plan), for its executive staff. The 457 Plan is a nonqualified deferred compensation plan subject to the Endowment net assets at July 1 $ 2,198 $ 635 $ 3,079 $ 5,912 provisions of the Internal Revenue Code Section 457. Expenses under the 457 Investment income 43 76 9 128 Plan approximated $120,000 and $170,000 for the years ended June 30, 2010 Net (depreciation) appreciation (710) (161) 5 (866) and 2009, respectively. The assets and liabilities of the 457 Plan are included Contributions – – 119 119 in investments and accounts payable in the accompanying consolidated statement Net assets released 153 (153) – – of financial position and amounted to approximately $546,000 and $437,000 Redesignation of net assets (288) – 288 – at June 30, 2010 and 2009, respectively. Endowment net assets at June 30 $ 1,396 $ 397 $ 3,500 $ 5,293
8. Lease Commitments LLS has adopted investment and spending policies for endowment assets The leases for premises, which LLS’s Home Office and chapters occupy, that attempt to provide a predictable stream of funding to programs supported expire on various dates through May 31, 2018 and provide for certain payments by its endowment funds while seeking to protect the original value of the gift. subject to escalation and periodic rate increases relating to real estate taxes, Under this policy, the endowment assets are invested in a manner that is intended operating expenses, and utilities. The Home Office lease expires in March 2016. to produce results consistent with LLS’s overall investment strategy. The approximate minimum aggregate future annual rental commitments are summarized as follows (in thousands): 10. Joint Costs Allocation Year ending June 30: For the years ended June 30, 2010 and 2009, LLS incurred joint costs for informational materials and activities that included fund raising appeals 2011 $ 7,502 as follows (in thousands): 2012 6,814 2010 2009 2013 5,139 2014 4,285 Fund raising $ 12,114 $ 12,834 2015 3,889 Patient and community service 1,049 1,013 Public health education 10,537 10,188 Thereafter 2,920 Total $ 30,549 Total $ 23,700 $ 24,035
34 National Leaders
Chairman of the Board Steven L. Hooker The Regence Group Portland, OR D. Gary Gilliland, MD Merck Vice Chair North Wales, PA Senior Scott Carroll Jackson Lewis Raanan Horowitz Cincinnati, OH Elbit Systems of America, LLC Staff Fort Worth, TX Secretary/Treasurer Kevin R. Ryan John M. Kamins Citrin Cooperman & Company, LLP Foster, Swift, Collins & Smith, PC Philadelphia, PA Farmington Hills, MI President & Chief Executive Officer Armand Keating, MD John E. Walter Board of Directors Princess Margaret Hospital James A. Beck Toronto, Ontario, Canada Chief Mission Officer Hefren-Tillotson, Inc. Research & Scientific Programs Butler, PA Joseph B. Kelley Louis DeGennaro, PhD Lilly USA, LLC Alexandra Mayes Birnbaum Washington, DC Chief Marketing Peartree Communications, Inc. & Revenue Officer New York, NY Marie Lauria, MSW Nancy L. Klein Chapel Hill, NC Robert A. “Spider” Cantley Chief Financial Officer Twain Harte, CA Steven Lilly Jimmy Nangle NRUCFC Elizabeth Clark, PhD, Herndon, VA Senior Vice President MPH, ACSW Chief Information Officer National Association of Social Workers Rodman N. Myers Jeff Como Washington, DC Honigman Miller Schwartz and Cohn Detroit, MI Senior Vice President Jorge Cortes, MD Public Policy The University of Texas Norbert J. Sieber George Dahlman M.D. Anderson Cancer Center NJS Consultants Houston, TX Miami, FL Senior Vice President Patient Services James H. Davis, PhD, JD Jay L. Silver Hildy Dillon Human Genome Sciences, Inc. Sugar Land, TX Rockville, MD Senior Vice President Mary Simmonds, MD Human Resources Timothy Durst New Cumberland, PA Philip Kozlowski Baker Botts LLP Dallas, TX Thomas R. Snyder Senior Vice President Nashville Bank and Trust Field Development Thomas L. Fitzpatrick Nashville, TN George Omiros Saint Gobain Corporation Worcester, MA William M. Ward, Jr. Senior Vice President Presbyterian Manors of Mid-America Revenue Generation David Frantze Wichita, KS Michael Osso Stinson, Morrison Hecker LLP Kansas City, MO Louise Warner Senior Vice President Chagrin Falls, OH Volunteer Engagement Paul N. Frimmer David Timko Loeb & Loeb, LLP Kathryn West, RN, MSN, OCN Los Angeles, CA Amgen Thousand Oaks, CA The Leukemia & Lymphoma Alan M. Gewirtz, MD Society of Canada University of Pennsylvania Michele Wong School of Medicine Synergex International Corporation President Philadelphia, PA Gold River, CA Nancy Allen
The Leukemia & Lymphoma Society 35 Chapter Offices
Illinois 651 West Washington Boulevard Suite 400 Alabama Chicago, IL 60661 100 Chase Park South n Suite 220 312.651.7350 Birmingham, AL 35244 205.989.0098 Indiana 941 East 86th Street n Suite 100 Arizona Indianapolis, IN 46240 New York 5 Computer Drive West n Suite 100 3877 North 7th Street n Suite 300 317.726.2270 Phoenix, AZ 85014 Albany, NY 12205 602.567.7600 Iowa 518.438.3583 8033 University Boulevard n Suite A 4053 Maple Road California Des Moines, IA 50325 Amherst, NY 14226 340 West Fallbrook Avenue n Suite 101 515.270.6169 716.834.2578 Fresno, CA 93711 559.435.1482 Kansas 555 Broad Hollow Road n Suite 403 6811 West 63rd Street Melville, NY 11747 n 6033 West Century Boulevard Suite 300 n 631.752.8500 Cloverleaf Building #1 Suite 202 Texas Los Angeles, CA 90045 Shawnee Mission, KS 66202-4001 475 Park Avenue South n 8th Floor 8111 LBJ Freeway n Suite 425 310.342.5800 913.262.1515 New York, NY 10016 Dallas, TX 75251
n 765 The City Drive South Suite 260 300 North Main n Suite 300 212.376.7100 972.996.5900 Orange, CA 92868 Wichita, KS 67202 1311 Mamaroneck Avenue n Suite 130 5005 Mitchelldale n Suite 115 714.481.5600 316.266.4050 White Plains, NY 10605 Houston, TX 77092 2143 Hurley Way n Suite 110 914.949.0084 713.680.8088 Sacramento, CA 95825 Kentucky 301 East Main Street n Suite 100 n 916.929.4720 North Carolina 950 Isom Road Suite 125 Louisville, KY 40202-1077 San Antonio, TX 78216 401 Harrison Oaks Boulevard n Suite 200 9150 Chesapeake Drive n Suite 100 502.584.8490 210.377.1775 San Diego, CA 92123 Cary, NC 27513 919.367.4100 858.277.1800 Maryland Virginia 11350 McCormick Road 5511 Staples Mill Road n Suite 202B 221 Main Street n Suite 1650 Ohio Executive Plaza lll n Suite 100 Richmond, VA 23228 n Suite H San Francisco, CA 94105 Hunt Valley, MD 21031 2300 Wall Street Cincinnati, OH 45212 804.627.0400 415.625.1100 410.891.1999 513.361.2100 675 North First Street n Suite 1100 Washington San Jose, CA 95112-5156 Massachusetts 23297 Commerce Park 530 Dexter Avenue North n Suite 300 408.490.2666 9 Erie Drive n Suite 101 Cleveland, OH 44122 Seattle, WA 98109 Natick, MA 01760 216.910.1200 206.628.0777 Colorado 508.810.1300 n Suite E 5353 West Dartmouth Avenue 2225 City Gate Drive Washington D.C. Columbus, OH 43219 Suite 400 Michigan 5845 Richmond Highway n Suite 800 Denver, CO 80227 1421 East Twelve Mile Road n Building H 614.476.7194 Alexandria, VA 22303 303.984.2110 Madison Heights, MI 48071 703.399.2900 248.581.3900 Oregon/SW Washington/ Idaho/Montana (OSWIM) Connecticut Wisconsin 9320 SW Barbur Boulevard n Suite 140 372 Danbury Road n Suite 200 Minnesota 200 South Executive Drive n Suite 203 Wilton, CT 06897 8441 Wayzata Boulevard n Suite 340 Portland, OR 97219 Brookfield, WI 53005 203.665.1400 Golden Valley, MN 55426 503.245.9866 262.790.4701 763.852.3000 Delaware Pennsylvania 555 North Lane n Suite 5010 100 West 10th Street n Suite 209 Mississippi/Louisiana Wilmington, DE 19801 3636 South 1-10 Service Road Conshohocken, PA 19428 Canada 302.661.7300 Suite 304 610.238.0360 Canada Corporate Metairie, LA 70001 800 Corporate Circle n Suite 100 804-2 Lansing Square Florida 504.837.0945 Harrisburg, PA 17110 Toronto, ON M2J 4P8 2 Oakwood Boulevard n Suite 200 717.652.6520 416.661.9541 x104 Hollywood, FL 33020 Missouri 954.744.5300 77 West Port Plaza n Suite 101 333 East Carson Street n Suite 441 BC/Yukon Region Street Louis, MO 63146-3111 Pittsburgh, PA 15219 310-1682 West 7th Avenue 3319 Maguire Boulevard n Suite 101 314.878.0780 412.395.2873 Vancouver, BC V6J 4S6 Orlando, FL 32803 604.733.2873 407.898.0733 Nebraska Rhode Island Région de Québec 10832 Old Mill Road n Suite 200 1210 Pontiac Avenue 4360 Northlake Boulevard n Suite 109 Omaha, NE 68154 Cranston, RI 02920 705-1255 University Street Palm Beach Gardens, FL 33410 Montreal, QC H3B 3W1 402.344.2242 401.943.8888 561.775.9954 514.875.1000
3507 East Frontage Road n Suite 300 New Jersey South Carolina Ontario Region Tampa, FL 33607 14 Commerce Drive n Suite 301 107 Westpark Boulevard n Suite 150 1502-480 University Avenue 813.963.6461 Cranford, NJ 07016 Columbia, SC 29210 Toronto, ON M5G 1V2 908.956.6608 803.731.4060 416.585.2873 Georgia 3715 Northside Parkway New Mexico Tennessee Prairies Region Building 400 Northcreek n Suite 300 3411 Candelaria NE n Suite M 404 BNA Drive n Suite 102 2020-10th Street NW Atlanta, GA 30327 Albuquerque, NM 87107 Nashville, TN 37217 Calgary, AB T2M 3m2 404.720.7900 505.872.0141 615.331.2980 403.263.5300
36 CovBc.indd 1 11/9/10 5:39 PM